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Abstract 
 
p53 is a transcription factor known to induce apoptosis via transactivating the 
expression of pro-apoptotic proteins and by directly activating the mitochondria apoptotic 
pathway. p53 is also found to be mutated in 50% of human cancers with some of these 
tumours overexpressing both wild type (WT) and mutant p53. Overexpression of the p53 
protein has been implicated with the more aggressive nature of these tumour cells, suggesting 
a possible gain-of-function of such mutants. In this study, the involvement of p53 in 
apoptosis via the caspase pathway was investigated. WT-p53 and three mutant p53 with 
mutations at the 1) N-terminus (D42Y), 2) central domain (R175H) and 3) C-terminus 
(R337H) were selected. The data collected demonstrated that p53 was able to inhibit the 
cleavage of caspases early in the apoptotic pathway. In vitro assays showed that addition of 
recombinant WT and the mutant p53 inhibited the cleavage of both caspase-9 and caspase-3 
and subsequently PARP, while overexpression of p53 in mammalian cells yielded the same 
inhibition profile in vivo. Conversely, removal of p53 via siRNA and immunodepletetion 
showed accelerated caspase-9 activity and cleavage. Immunoprecipitation experiments and 
recombinant assay systems suggest that the inhibition by p53 is targeted at the active cleaved 
caspase-9. In addition, the presence of p53 (WT or mutant) in p53-null cells were able to 
confer a higher survival rate. These data therefore demonstrate that p53 may have an 
additional anti-apoptotic role via the inhibition of caspase-9, which is often masked by its 
pro-apoptotic functions. This anti-apoptotic role could manifest itself in a cancer background 
overexpressing mutant p53 which has lost its transcriptional activity and hence its ability to 
induce apoptosis via the induction of pro-apoptotic genes such as PUMA and NOXA. This 
newly discovered role of p53 could potentially explain the aggressive nature of cancers which 
overexpress p53.  
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Chapter 1 
 
Introduction 
 
p53 is a transcription factor first discovered in 1979 as a mouse protein which 
interacts with the large T-antigen produced in simian virus 40 (SV40)-transformed cells [1]. 
The discovery came at a time when cancer research was focused on tumour-causing viruses.  
In the 1970s, scientists were characterising proteins overexpressed in virus-
transformed cells. Antibodies generated to detect these viral oncoproteins led to the discovery 
of the SV40 large and small T-antigen. Subsequent work by Lane and Crawford [1] found a 
non-viral protein of 53kDa that often forms a complex with the large T-antigen. This finding 
was concurrently reported by other laboratories around the world [2-5]. p53 was also later 
found in human cells, with a large quantity of this protein present in tumour cell lines that 
arose from spontaneous mutations or in SV40-transformed cells [6].  
Due to its association with the SV40 large T-antigen protein, p53 was initially thought 
to function as an oncogene. In addition, p53 was also discovered to co-precipitate with the 
E1B tumour antigen, produced by another small DNA virus, the adenovirus [7]. Similar to 
other oncogenes, p53 was found to be overexpressed in many tumours [8]. It was not until 
almost a decade later that p53 was instead established to be a tumour suppressor. 
As research on p53 progress, the p53 gene was cloned in several laboratories. 
However, they soon realized that not all the cloned p53 genes were able to result in cell 
transformation. Around the same time, p53 was also discovered to be inactivated by retroviral 
insertion in an Abelson murine leukaemia virus-transformed mouse cell line [9]. In another 
human derived leukaemic cell line, HL60, the p53 coding sequence was found to be almost 
completely deleted [10]. Similarly, p53 knock-out mice displayed rapid malignant 
progression [11]. These findings pointed to the fact that p53 might be an important gene in 
preventing the transformation of cells. As the researchers‟ findings converged, it was finally 
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revealed that the transformation abilities of p53 initially observed were due to the mutant 
forms of the p53 gene [12,13], while the wild-type (WT) p53 actually functions as a tumour 
suppressor [14,15]. 
Since then, p53 has been shown to be implicated in most forms of cancer. Over the 
decades, 50% of human cancers were found to have mutations in the p53 gene which directly 
compromise the functions of the p53 protein it encodes, while a large proportion of the rest 
have mutations in other genes which affect the functions of this important protein [16]. It is 
hence not surprising that current cancer research has focused on 1) p53 itself; 2) the 
numerous other proteins that either interacts directly with p53; 3) or on its transcriptional 
products; producing no less than 50,000 publications which are identified in a Pubmed search 
on “p53”.  
Besides being heavily implicated in cancer, p53 was shown to be involved in multiple 
cellular processes ranging from cell cycle arrest [17], senescence [18], stress [19],  to 
apoptosis [20,21]. With its myriad roles, it is no wonder that mutations in this gene would 
result in considerable disturbance in cellular functions, affecting the survival of the cell, the 
organ, or the individual whose cells harbour the mutation(s). 
 
1.1 Structure of p53 
 
p53 is a polypeptide of 393 amino acids that is organized into five distinct domains 
(Figure 1.1). The amino-terminus encodes the transactivation domain (TAD), necessary for 
activating the target genes downstream of the promoter to which it binds. A Nuclear Export 
Signal (NES) is also within this domain. This is followed by the Proline-Rich Domain (PRD) 
which is critical for protein-protein interaction [22]. Next lies the DNA-binding domain 
(DBD), which is responsible for binding to the DNA consensus recognition element unique to 
p53 [23]. Situated near the carboxyl terminus are several Nuclear Localisation Signal (NLS) 
as well as a NES. The NES is located within the Oligomerisation domain, also known as the 
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Tetramerisation Domain (TD). The last domain is the basic domain (BD), characterized by 
the highly basic amino acids which make up this segment. When p53 is activated, the protein 
forms a tetramer which allows the complex to remain in the nucleus and bind specifically to 
the promoters of its target genes [24,25]. 
 
 
 
Figure 1.1. Structure of p53. Diagram showing the various domains of p53 and the amino acid residues that 
spans the domain [26].  
 
 
1.1.1 The Transactivation and the Proline-Rich Domain 
 
The TAD and the PRD (amino acid resides 1-101) make up the N-terminus of the p53 
protein. Both domains are responsible for interacting with the transcriptional machinery of 
the cell to drive the expression of genes responsive to p53.  
The TAD has a high content of aspartic and glutamic acid residues while the PRD, as 
the term suggest, consist of very high number of proline residues. Within the PRD region, 
five PXXP repeating sequences can be found, where P stands for Proline while X refers to 
any amino acid.  
Based on the target genes that are activated, both domains can be reorganized into 
Activation Domain (AD) 1, which spans from amino acids 1-42, and AD2, which consists of 
amino acids 43-92. AD1 has been shown to drive the expression of genes involved in cell 
cycle arrest, while AD2 is responsible for transactivating genes involved in apoptosis [27]. 
Indeed, mutations to critical resides in both domains impairs the transactivation of the 
corresponding group of genes. The L22Q/W23S double mutation in AD1 resulted in 
apoptosis but not cell cycle arrest [28], while mutations to residues 53 and 54 (W53Q/F54S) 
Chee Lai Yuen  
17 
 
or deletion of residues 43–63 or 64–92 resulted in p53 proteins that are unable to induce 
apoptosis [29].  
As the main function of the TAD and PRD is to transactivate genes, these domains 
have known interactions with several proteins involved directly in transcription. For example, 
the AD1 interacts with TATA box binding protein (TBP), TBP associated factors (TAF) 
TAFII31, TAFII70, p300/CBP and Pin1, while the AD2 interacts with p300/CBP, Pin1 and 
other transcriptional proteins. In addition, the PRD can interact with proteins with SH3 
domains [30]. Pin1 positively regulates AD1 and AD2 through isomerisation of prolines 
within AD1 and AD2, resulting in conformational changes in p53. The conformational 
change stabilizes p53, which then promotes its DNA binding and transactivation functions 
[31].  
An interesting fact to note within this region is that the PRP houses the polymorphic 
residue 72, which can either be a proline (P72) or arginine (R72), hence altering one of the 
five PXXP regions. The PXXP regions share similar properties to SH3-binding proteins, and 
thus were proposed to be involved in p53-mediated apoptosis [32] and for suppressing 
tumour growth [22].  The replacement of proline by arginine at residue 72 would cause a 
disturbance to the functions of p53, and has been shown to affect p53 activity. Interestingly, 
haplotype analysis has shown a strong emergence of the R72 allele which is clearly being 
actively selected for in humans living away from the equator [33].  
 
1.1.2 The DNA-Binding Domain 
 
 The DBD occupies the central region of the p53 proteins and spans residues 93 to 
292. The core function of this domain is to bind to the promoters of p53-responsive genes 
during the transactivation process. The promoters of these genes bear a canonical p53-
responsive element (RE) consisting of one or two decamers of the sequence 
RRRCWWGYYY (where R=purine, C=cytosine, W=adenine or thymidine, G=guanine, and 
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Y=pyrimidine) with a spacing of 0 to 13 base pairs between each decameric recognition 
sequence [23]. Studies by Cho [34], showed that monomeric p53 binds to a pentameric 
sequence within the p53-RE, while an active tetrameric p53 binds to the full consensus 
sequence.  
 While the majority of p53-responsive genes carry the p53-RE within their promoters, 
research has shown that p53 can bind to other DNA sequences. For example, p53 can bind to 
the pentanucleotide polymorphicmicrosatellite (TGYCC)n sequence of the p53-induced gene 
3 (PIG3) [35] and also the 12-bp palindromic sequence (CCCCACGTGAGG) of the 
phosphatase of activated cells 1 (PAC1) [36] gene. The diverse recognition sequences allow 
p53 to control and transactivate more genes in response to various cellular signals that 
converge on the activation of p53. 
 The binding of p53 to the REs is facilitated by the anti-parallel β-sheets that are 
formed by the DBD. Specific amino acid residues within the DBD form critical points of 
contact between the DBD and the DNA. For example, R273 associates with the DNA 
phosphate backbone while R280 interacts with the major groove [34]. As such, it is not 
surprising to find that almost 75% of p53 mutations in human tumours are in the central 
region of p53 [37]. One such mutation is the R273H. This mutation affects the binding of p53 
to DNA [38], hence resulting in reduced transactivation of p53-responsive genes. A study by 
Bissonnette [39] showed that the R273H p53 mutant was unable to induce the expression of 
the pro-apoptotic, p53-responsive p21
WIP1/CIP1
 gene.  
Another hotspot mutation, R175H, disrupts the DBD structure by destabilizing the β-
sandwich core domain and as a result the mutant lacks the appropriate scaffold for proper 
interaction with DNA. This seems to be a more potent mutation as it was able to transform 
mammalian epithelial cells when overexpressed, as compared to the R273H mutation, which 
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only induces prolonged cell survival [40]. Hence, it is clear that mutations in this domain can 
have undesirable effects on cells and their survival. 
 
1.1.3 The Tetramerisation Domain 
 
 Tetramerisation of p53 is very important for its function as a transcription factor [41], 
as transactivation of p53-responsive genes can only take place when p53 tetramerises. The 
TD comprises of residues 326-356. A single TD folds to form the secondary structures of a β-
sheet followed by an α-helix. p53 monomers dimerize through anti-parallel β-sheet and α-
helix interactions. The dimers then tetramerise and are stabilized through hydrophobic forces 
generated by the helix–helix interactions [42].  
 Although mutations in this domain are less common than those in the DBD, the 
consequences of such mutations are still detrimental to p53‟s function, and the overall 
survival of the organism. A common mutation within the TD is R337H. This mutation has 
been implicated in the tumorigenesis of 36 children suffering from adrenocortical carcinoma 
(ACC) [43]. In this case study, the R337H mutation occurred in 35 out of the 36 children. 
The mutant R337H was found to be less stable and highly sensitive to pH, which could then 
contribute to the high incidence of ACC in these children. In a more recent study, a newly 
identified p53 mutant, K351N (found in cisplatin-resistant ovarian carcinoma cell line 
(A2780-cis) has been shown to have reduced stability and was further demonstrated to lack 
the ability to transactivate pro-apoptotic genes such as Bax [44] upon cisplatin challenge.  
 Overall, mutations in the TD disturb the tetramerisation of p53 and its ability to 
transactivate crucial genes involved in processes such as apoptosis, which could then possibly 
contribute to the tumorigenesis in cases such as the one mentioned above. 
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1.1.4 The Basic Domain 
 
The BD spans the last 30 amino acids of the p53 protein. It is referred to as the BD as 
it largely consists of basic amino acids such as lysine and arginine. Unlike the DBD and the 
TD, this domain has no regular secondary structure. However, it does show some secondary 
structure upon association with specific proteins. For example, when complexed with S100B 
or phospho-CDK2-cyclin A, it folds to form a helical structure [45,46], while its binding to 
the deacetylase Sir2 or to the bromodomain of CBP results in an extended conformation 
[47,48]. 
However, the BD‟s contribution to the function of p53 lies not in the structure but the 
numerous post-translational modifications that could take place in the residues of this 
domain. These post-translational modifications include phosphorylation, methylation, 
acetylation, ubiquitination, neddylation, or sumoylation [49]. The regulation of p53 will be 
further discussed in Section 1.3.  
 
1.2 The Different Roles of p53 
 
Since the discovery of p53 as a tumour suppressor, increasing evidence has been 
gathered to uncover novel functions of p53 that implicate the protein in enhancing cell 
survival. Generally, in cells damaged by cytotoxic insults, the role of p53 is to activate 
pathways which either repair this damage; or induce the damaged cells to enter apoptosis 
once these cells are deemed “beyond repair”. The section here aims to bring attention to some 
of the more widely studied roles of p53. 
 
1.2.1 In Cell Cycle 
 
One of the roles of p53 is in controlling the progression of the cell cycle during cell 
division. p21
WAF1/CIP1
, a transcriptional target of p53, is an inhibitor of cyclin-dependent 
kinases (CDKs). CDKs are key regulators of the cell cycle, allowing cells to enter S phase 
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from G1 phase. When DNA damage is detected, the induced expression of p21
WAF1/CIP1
 by 
p53 halts cell cycle progression [17], enabling the damaged DNA to be repaired before the 
cell replication cycle is resumed.  
In addition, p53 can also control cell cycle progression in the G2/M phase. A protein 
that functions in this is the 14-3-3σ. The induced expression of 14-3-3σ by p53 upon DNA 
damage helps to sequester the cyclin B1–CDK1 complexes outside the nucleus. This 
cytoplasmic mislocalisation of the complex maintains the cell in G2 arrest [50,51]. Another 
protein involved in this checkpoint is the Gadd45α protein. A p53-responsive protein, it binds 
to the proliferating cell nuclear antigen (PCNA) protein which is involved in DNA replication 
and repair. Thus, p53 functions to stimulate DNA repair through the expression of Gadd45α 
while at the same time inhibit the progression of cells into the mitotic phase [52]. 
Hence, the role of p53 here is to maintain genomic stability, minimize the replication 
of cells with DNA damage and mutation, and indirectly stimulate the repair of such damaged 
DNA. 
 
1.2.2 In Senescence 
 
As a more permanent control of aberrant cell proliferation, p53 is involved in 
inducing senescence in cells. Cells that are senescent cease to proliferate and accumulate G1 
DNA content, indicating an arrest prior to the DNA replication stage in the cell cycle [53]. 
Plasminogen activator inhibitor-1 (PAI-1), a downstream target gene of p53, participates in 
this aspect to induce senescence in DNA damaged cells. Its knockdown in primary mouse 
embryo fibroblast through RNA interference resulted in continual cell replication, suggesting 
its importance in preventing oncogenic transformation in such damaged cells [54]. 
DNA damage such as that induced by dysfunctional telomeres is one of the triggers of 
senescence. In this case, upstream kinases such as ATM (ataxia-telangiectasia mutated) are 
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activated, which in turn phosphorylate factors such as checkpoint kinase (CHK)1, which then 
activate p53 [55].  
Crosstalk between the senescence and the cell cycle arrest pathways is evident as 
activated p53 in senescence engages the same pathway as in cell cycle control involving 
p21
WAF1/CIP1
 to stall cell proliferation.  
 
1.2.3 In Oxidative Stress 
 
Besides responding to cellular stress conditions such as DNA damage, hence 
activating cell cycle arrest or senescence, p53 also participates in activating pathways in 
response to conditions such as reactive oxygen species (ROS) and hypoxia. p53 reacts to the 
presence of ROS by inducing the expression of aldehyde dehydrogenase 4 (ALDH4)[19] and 
TIGAR (TP53-induced glycolysis and apoptosis regulator)[56] to reduce intracellular levels 
of ROS. p53 can also induce the expression of GLS2 (glutaminase 2), which increase the 
levels of glutathione, thereby also reducing the ROS levels [57]. Fast growing tumour cells 
often face hypoxic conditions where Hypoxia Inducible Factor 1-alpha (HIF 1-α) is activated, 
which in turns activates p53. p53 is then able to control cell proliferation in this oxygen-
deprived environment by activating cell cycle arrest [58]. 
 
1.2.4 In Autophagy 
 
 In response to cellular stress such as nutrient deprivation [59] and serum withdrawal 
[60], the process of autophagy is induced. Autophagy (strictly termed macroautophagy, but 
often referred to as autophagy), is an evolutionary conserved membrane-trafficking process 
that operates at basal levels under normal conditions as a means of degrading cytosolic 
proteins and organelles [61]. Cytosolic proteins and damaged organelles such as the 
mitochondria are contained in double-membraned vesicles known as autophagosomes, which 
then fuse with lysosomes in the cytoplasm, to form the autolysosomes. The contents of the 
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autolysosomes are then degraded by the lysozymes, and released back into the cytoplasm 
[62]. This process allows for the recycling of cellular metabolites to counteract the effects of 
lowered levels of essential building blocks during nutrient deprivation.  
 The role of p53 in this aspect is to transactivate DRAM (damage-regulated autophagy 
modulator), which encodes a lysosomal protein that induces autophagy during cellular stress 
such as DNA damage [61].  
 Another set of genes that are transactivated by p53 are the sestrins1 and sestrins2 
[63], which encodes proteins that inactivate mTOR (mammalian target of rapamycin), a 
kinase that inhibits autophagy [64].  
 However, studies by Tasdemir [65] demonstrated that cytoplasmically localised p53 
actually inhibits autophagy. In fact, autophagy could only be induced if the function of the 
cytoplasmic p53 has been inactivated through the use of inhibitors such as pifithrin-α, the 
deletion of the p53 gene or depletion of the protein. The implications of autophagy inhibition 
by cytoplasmic p53 in cancer will be discussed later.  
 
1.2.5 p53 and Apoptosis 
 
Another important function of p53 is in the induction of apoptosis. If cellular damage 
are beyond repair even after the activation of cell cycle arrest, p53 will then initiate the 
process of apoptosis to rid the body of such damaged cells. As a transcriptional factor and 
tumour suppressor, p53 has been shown to transactivate several genes whose products 
participate in the apoptotic pathway.    
Apoptosis is a term coined by Kerr [66] to describe an intrinsic cell suicide program. 
Apoptosis is a regulated mode of cell death that occurs throughout development in all 
multicellular organisms. It is also involved in the death of cells during diseases [67,68] or 
when they are damaged [69,70], in tissue remodelling during embryogenesis [71,72], and in 
maintenance of homeostasis and immune functions [73]. Cells dying via apoptosis show 
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distinct morphological characteristics such as chromatin condensation, nuclear fragmentation, 
cell shrinkage, cytoplasmic condensation and apoptotic body formation [74]. The apoptotic 
bodies are then phagocytosed by macrophages, therefore preventing inflammation [75]. 
In order to better understand the mechanism in which a cell enters apoptosis, it is 
important to study in greater detail one of the main protein families involved in the apoptotic 
process, the caspases. The subject of this thesis, the interconnection between p53‟s functions 
and caspases will be highlighted. 
 
1.2.5.1 The Caspase Family 
 
The caspases are a distinct, highly conserved class of intracellular cysteine proteases. 
This family of proteins is characterized by their almost absolute specificity for aspartic 
residues in their substrate [76]. Caspases are constitutively expressed as inactive proenzymes 
[77]. They are only activated upon reception of death stimuli e.g. serum withdrawal. 
Activation of caspases requires the proteolytic cleavage at two sites within the protein [78]. 
The released subunits then assemble to form heterotetramers that are enzymatically active 
[79].  
Caspases are divided into two subgroups based on their functions in the apoptotic 
pathways. The „initiator‟ caspases consisting of caspases-1, -2, -4, -5, -8, -9, -10, -11, and -12 
receive the initial death stimulus. The activation of this cascade of caspases usually converges 
upon a common set of the downstream „effector‟ caspases. Effector caspases (consisting of 
caspases-3, -6, -7 and -14) are directly responsible for the cleavage of housekeeping proteins, 
causing death to the cells and also giving rise to the morphological characteristics observed 
during apoptosis. They can also inactivate proteins which inhibit apoptosis by cleaving them 
into fragments, for example the cleavage of Poly(ADP-ribose) polymerase (PARP), a nuclear 
protein involved in DNA repair [80].  
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In general, two different types of death stimuli exist which are able to activate distinct 
sets of caspases within the cells. These lead to the separate grouping of the caspases into two 
major apoptotic pathways. The two pathways are namely the death receptor (Fas-ligand)-
mediated and the mitochondria-mediated pathways. The interaction of these two pathways 
and p53 are illustrated in Figure 1.2.   
 
1.2.5.2 p53 and Fas-Ligand Pathway 
 
 The death receptor-mediated pathway is activated when ligands such as the tumour-
necrosis factor (TNF) binds to the death receptor found on the surface of the cell. This leads 
to the recruitment of adaptor proteins such as FADD (Fas-associated death domain) and 
procaspase-8 to the receptor [81]. p53 is involved in this pathway through the transcriptional  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. An illustration of the Role of p53 and Other Proteins Involved in the Various Apoptotic 
Pathways [82]. 
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activation of genes encoding the death receptors located at the plasma membrane, including 
the Fas receptor [83] and DR4 [84]. This positive feedback system allows cells which are 
targeted for apoptosis to receive the death signal promptly for their ultimate destruction. 
 
1.2.5.3 p53 and the Mitochondria Pathway 
 
 The mitochondrial apoptotic pathway is a complex network involving the caspases as 
well as the Bcl family of proteins. Cellular stress such as cytotoxins can damage the 
mitochondria, resulting in the disturbance of the membrane potential and the release of 
mitochondrial proteins such as cytochrome-c. Cytochrome-c, when present in the cytosol, 
triggers the formation of the complex „apoptosome‟. The apoptosome is composed of Apaf-1, 
cytochrome-c itself and caspase-9. This apoptosome complex can trigger the activation of 
both caspase-9 and caspase-3 within, thus leading to apoptosis [85].   
 Regulators of this pathway are provided by members of the Bcl family, which are 
either anti-apoptotic or pro-apoptotic. Anti-apoptotic members such as Bcl-2 and Bcl-xL have 
been shown to delay the activation of caspases by inhibiting the release of cytochrome-c 
[86,87]; while pro-apoptotic members such as Bax accelerates apoptosis by disturbing the 
mitochondrial potential via the formation of a complex within the mitochondrial membrane, 
thereby facilitating the release of cytochrome-c [88].  
 Bax is a p53-inducible protein. In normal cellular conditions, Bax is found associated 
with anti-apoptotic proteins such as Bcl-2 and Bcl-xL, while p53 is also kept in check 
through the association with these proteins [89]. PUMA is another transcriptional target of 
p53. In cellular stress, upregulation of PUMA by p53 allow the displacement of Bax [90] and 
p53 from Bcl-2 and Bcl-xL. This in turn allows Bax to induce apoptosis through the 
mitochondria, while p53 can further induce the upregulation of more pro-apoptotic genes to 
positively regulate this pathway. The importance of Bax in apoptosis was demonstrated in 
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report which showed that decreased levels of Bax correlated with lower apoptosis and 
increased tumour growth in mouse [91]. 
 
1.2.6 Transcription-Independent Role of p53 in Apoptosis 
 
The majority of research on p53 is centred on its transcriptional role and its target 
genes. Judging from the extensive array of p53 target genes involved in the diverse cellular 
functions, the heavy focus on this area is more than justified. However, p53 does possess the 
ability to induce apoptosis that is independent of transcription.  
One such clue came from the study of a temperature sensitive p53 mutant. At the 
permissive temperature, the upregulation of pro-apoptotic genes and apoptosis took place as 
expected. However, when drugs were added to inhibit transcription and translation, 
expression of the p53 target genes was abolished while apoptosis could still take place [92]. 
In other studies by Haupt [93,94], p53 proteins that did not possess the transactivation 
domain were able to induce apoptosis, although the known target genes of p53 in apoptosis 
were not found to be upregulated. Further evidence came from Marchenko [95], which 
demonstrated the localisation of p53 (a predominantly nuclear localised protein) to the 
mitochondria upon challenge by a cytotoxin e.g. camptothecin. This relocalisation of p53 was 
observed to be rapid and preceded changes in the outer mitochondrial membrane (OMM) 
potential, cytochrome-c release, and procaspase-3 activation. 
 In 2004, Chipuk [20] showed the activation of Bax directly by p53. The activated Bax 
induced the collapse of mitochondria potential, leading to release of cytochrome-c and 
caspase-9 and caspase-3 activation. This novel role of p53 was demonstrated convincingly 
using an in vitro system consisting of recombinant p53, recombinant Bax and isolated 
mitochondria. The combination resulted in the release of cytochrome-c, proving the 
transcription-independent role of p53 in apoptosis. 
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 Another interacting partner of p53 in this transcription-independent role is Bak. Bak is 
a multidomain protein which is found integrated into the lipid layer of the outer mitochondria 
membrane. Similar to Bax, Bak is able to oligomerise to form a pore on the OMM, hence 
disrupting the membrane potential and inducing apoptosis via the release of cytochrome-c 
[96]. A small percentage of cellular p53, which is localised in the mitochondria, was shown 
to interact with Bak and induce its oligomerisation to result in the release of cytochrome-c 
upon cytotoxic challenge [97,98].  
 Interestingly, the transcriptional-independent induction of apoptosis by p53 is 
dependent on the different cellular location of p53. Upon cytotoxic stimulus, p53 can 
translocate from the nucleus into the cytoplasm [20,99] and the mitochondria [95,100]. The 
cytoplasmically localised p53 can then activate Bax while the mitochondria-located p53 
activates Bak.  
Apart from causing the release of cytochrome-c through inducing OMM 
permeabilization through Bak and Bax, p53 can also cause the same phenomenon by 
antagonizing the actions of anti-apoptotic proteins such as Bcl-xL and Bcl-2, allowing 
cytochrome-c release and apoptosis [21].  
 Hence, p53 performs its tumour suppressive functions not only by inducing the 
expression of gene in response to cellular stress and apoptosis, but also by directly interacting 
with proteins involved intimately in the apoptotic regulation. Its non-nuclear localisation also 
serves to ensure that destruction of the damaged cell can take place efficiently when the need 
arises. 
 
1.3 Regulation of p53 
 
 From the diverse cellular situations that initiate the transactivation of the multitude of 
genes that are responsive to p53, it is no doubt that p53 functions as a node for organizing 
whether the cell responds to various types and levels of stress with cell cycle arrest and DNA 
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repair, senescence, cell metabolism, autophagy or apoptosis. Being termed the “guardian of 
the genome” [101] and the “cellular gatekeeper” [102], it is of utmost importance for the cell 
to regulate a protein such as p53.  
 
1.3.1 Negative Regulation of p53 – MDM2 and Ubiquitination 
 
Given that p53 is a tumour suppressor and that a constitutively active p53 could 
potentially result in dire outcomes, a normal healthy cell would want to keep this protein in 
an inactivated state and its cellular abundance in check. The stability and half-life of p53 is 
tightly regulated by the MDM2 (Murine Double Minute 2) [103], sometimes referred to as 
HDM2 in humans. By far, MDM2 is the most well-studied regulator of p53 stability.  
p53 is constantly bound to MDM2 via the TAD [104] and DBD [105]. MDM2 is an 
E3 ligase responsible for targeting p53 for ubiquitin-dependent degradation [106]. It transfers 
ubiquitin moieties onto the lysine residues of p53 [104], which then exposes the NES in the 
C-terminus of p53, allowing it to dissociate from MDM2 and translocate from the nucleus 
into the cytoplasm [107]. In the cytoplasm, an ubiquitinated p53 is recognized by the 26S 
proteosome, which then targets it for degradation [108]. The importance of MDM2 in 
regulating p53 was highlighted in two studies. It was found that even when an extra copy of 
p53 were added to cells, a reduced expression of MDM2 were sufficient to regulate p53 
levels and maintain homeostasis [109,110]. In addition, mice that were MDM2
-/-
 were not 
viable and the embryonic lethality were rescued by a concurrent deletion of the p53 gene, 
suggesting that the regulation of p53 by MDM2 is an essential cellular function [111]. It is 
therefore not surprising that over a third of human cancers with wild-type p53 contain 
multiple copies of MDM2 gene [112].  
The ubiquitination of p53 by MDM2 is effective in regulating the stability and half-
life of p53. The process of ubiquitination not only reduces the levels of p53, it also targets 
p53 into the cytoplasm, thereby reducing its levels in the nucleus, and hence its ability to 
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transactivate its target genes. At the same time, the binding of MDM2 to the TAD of p53 
further prevents p53 from inducing the expression of its target genes [113].  
In addition to MDM2, MDMX (sometimes referred to as MDM4), a MDM2 homolog, 
can interact and form a heterodimer with MDM2. This heterodimer of MDM2-MDMX was 
found to be a better ubiquitin ligase for p53, as compared to a MDM2 homodimer [114]. 
Similar to MDM2, MDMX
-/-
 mice are embryonic lethal and can be rescued by the concurrent 
deletion of the p53 gene, hence demonstrating the importance of MDMX in p53 regulation 
[115].  
 
1.3.2 Negative Regulation of p53 – Post-Translational Modifications of p53 
  
 Besides ubiquitination, p53 is extensively modified post-translationally through 
phosphorylation, acetylation, methylation, sumoylation and neddylation. It appears that most 
post-translational modifications serve to enhance p53 stability and activities, with a few as 
negative regulators of p53. To show the extent of p53 modification, a beautiful diagram by 
Boehme and Blattner [49] has been included as Figure 1.3. 
Phosphorylation at the serine and threonine residues of p53 is common. 
Phosphorylations at serine 362 and 366, mediated by IκB kinase 2 (IKK2), targets p53 for 
degradation [116]. Also, COP9 signalosome kinase (CSN-K) has been found to promote p53 
degradation by phosphorylating threonine 155 [117].  
Methylation is another post-translational modification of p53, although not as 
extensive as phosphorylation. Huang [118] found that the methylation of lysine 370 by 
SMYD2 (a lysine methyltransferase) reduced the binding of p53 onto the promoters of genes 
such as p21, and that knockdown of SMYD2 correlated with increased p21 expression and 
apoptosis.  
 Neddylation is a somewhat not so common form of modification. It involves the 
covalent addition of ubiquitin-like protein Nedd8 to the lysine residues of the modified 
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protein [119]. MDM2 has been found, among other proteins, to neddylate lysine residues 
K370, K372 and K373 in the C-terminus of p53 [120], thereby inhibiting its transcriptional 
activities. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Negative Regulation of p53 through Post-Translational Modifications and other p53 
Interacting Proteins. Illustration of the ubiquitination, phosphorylation, methylation and neddylation sites on 
p53 that increase its stability in the cell. All modifications are colour-coded with the corresponding protein 
responsible for the modifications identified in the same diagram. 
 
  
1.3.3 Negative Regulation of p53 – The Role of its Interacting Partners 
 
 Through the years of research, interacting partners of p53 that regulate its activities 
were uncovered. Proteins that bind to the N-terminus and DBD of p53 generally suppress the 
transactivation properties of p53, for example MIF (macrophage migration inhibitory factor) 
[121]. Others associate with the TD of p53, thereby repressing p53 functions through 
preventing the formation of p53 tetramers. Examples of such proteins can be found in the 
S100 family, which prevent p53-mediated transactivation by hindering the oligomerisation 
and retaining p53 in the cytoplasm [122]. iASPP binds to the PRD of p53 and specifically 
inhibits the expression of Bax [123]. Apart from affecting the transactivation properties of 
p53, there are also proteins which can regulate its transcriptional-independent functions. Bcl-
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2 interacts with p53 at the DBD to prevent the induction of apoptosis through p53-dependent 
activation of Bax and Bak proteins at the mitochondria [20,21].  
 
1.3.4 Positive Regulation of p53 – Inhibiting the Inhibitor 
 
In normal physiological conditions, p53 is constantly produced but the levels are 
maintained low by the recurring ubiquitin activities of MDM2 or by the other proteins 
mentioned above. However, in conditions where the functions of p53 are needed, the level of 
the protein has to be elevated. One of the major ways of increasing the levels of p53 is to 
relieve its inhibition from the negative regulation of MDM2.  
To relieve this inhibition, phosphorylation of serine residues e.g. serine 20 within the 
TAD causes a conformation change, resulting in reduced affinity for MDM2 [124]. 
Tetramerisation of p53 then takes place, which hides the NES within the carboxyl terminus. 
Consequently, p53 is retained within the nucleus, allowing it to activate the expression of its 
target genes [25]. In addition, stability of p53 can also be enhanced by the degradation of its 
antagonizer MDM2, mediated by the alternate reading frame (ARF) protein, hence relieving 
p53 from the inhibitory actions of MDM2 [125].  
 
1.3.5 Positive Regulation of p53 – Changing the Facet of p53 
 
The stability and activity of p53 can also be mediated by post-translational 
modifications. Methylation at serine 372 by Set9 methyltransferase [126] and demethylation 
at lysine 382 by p53 binding protein-1 (53BP1) [127] increase the stability and thereby p53-
mediated response to cellular stress.  
Acetylation of p53 also plays a two-pronged role in stabilizing the protein. 
Acetylation of p53 can first disrupt its interaction with MDM2 [128] and MDMX [129], and 
subsequently increase the transactivation of pro-apoptotic genes such as Bax and p21 [130]. 
Acetylation of p53 is performed mainly through acetyltransferases such as p300/CBP [131]. 
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Major sites of acetylation include lysine 164, 320, 373 and 382 [129,130,132]. In addition, 
acetylation of lysine 320 enhances the cytoplasmic localisation of p53. This could then enable 
p53 to perform its apoptotic roles in the cytoplasm [133].  
The less common forms of post-translational modifications include neddylation and 
sumoylation. Studies on the process of neddylation seem to suggest that neddylated p53 are 
inactivated (as discussed in Section 1.3.2), while there are conflicting roles of sumoylation on 
p53. In any case, for the enhancement of p53, studies have shown that sumoylation activates 
p53 and induces the transcription of pro-apoptotic genes such as p21 [134,135].  
 
1.3.6 Positive Regulation of p53 – The Roles of Other Proteins 
 
 While some proteins serve to prevent the binding of p53 to the promoters, others 
function as activators of p53. Such positive regulators of p53 mainly interact with p53 at the 
DBD and the TD. Apoptosis simulating p53 protein (ASPP)-1, ASPP-2 [136,137] and 
hematopoietic zinc finger (Hzf) [138] are examples of such proteins. These proteins function  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. Positive Regulation of p53 through Post-Translational Modifications and other p53 
Interacting Proteins. Illustration of the ubiquitination, phosphorylation, methylation and neddylation sites on 
p53 that increase its stability in the cell. All modifications are colour-coded with the corresponding protein 
responsible for the modifications identified in the same diagram. 
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to enhance the transactivation of p53 target genes by stimulating the binding of p53 to DNA. 
Positive regulators that interact with the TD of p53 enhance the tetramerisation of p53, and 
thereby induce the expression of its target genes. The Ref-1 (Redox/Repair-1) [139] and 14-
3-3σ [140] belong to this group of proteins.  
 
1.3.7 Regulation of p53 by p53 
 
 To add on to the complexity of the regulatory network of p53, p53 itself can be 
involved in the regulatory process, thereby forming feedback loops which can either 
positively or negatively regulate its own activities. 
 The most commonly discussed and studied feedback loops involve p53 and MDM2. 
MDM2 itself is a transcriptional target of p53 [141]. In circumstances where p53 is activated 
and free from the antagonistic actions of MDM2, the activated p53 can drive the expression 
of its targets genes in response to the stimulus, including MDM2. The consequential elevated 
expression of MDM2 would then inhibit p53 and reduce its levels, hence forming a negative 
feedback loop. 
 p53 can also positively regulate its stability and activities through feedback loops 
involving other proteins. For example, 14-3-3σ has been identified as a p53-inducible protein 
and a negative regulator of the cell cycle. Induced expression of this protein by p53 act to 
inhibit the ubiquitination of p53 by MDM2, and also promote the transactivation activities of 
p53 by enhancing its ability to oligomerise [140]. This feed forward loop may be necessary in 
times where the cell cycle needs to be halted, in order for p53-induced proteins involved in 
DNA repair to function, thereby reducing the propagation of DNA defective cells.  
 
1.3.8 Regulation of p53 – A Delicate Balance 
 
From the discussion on the regulation of p53, it is evident that several cellular stresses 
could result in the activation of p53; and that p53 can be activated through modifications of 
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itself, and also interactions with other proteins. The process that p53 elicit, could have 
conflicting outcomes for the cell. For example, DNA damage induces cell cycle arrest and 
DNA repair, while it could also cause cell death through apoptosis. Senescence and 
ultimately apoptosis could also result from genomic instability and cell cycle arrest. So how 
does a cell determine the cell fate in the face of the myriad of pathways elicited by p53? 
 
 
 
 
 
 
 
 
 
Figure 1.5. p53 as a Node for Integrating Cellular Stresses and its Possible Response. The diagram shows 
the various cellular process that could lead to the activation of p53 (box in blue), and also the responses that p53 
can elicit (box in pink).  
 
 The answer lies in the controlling of the balance between the “activators” of each 
pathway. For example, while DNA damage could induce expression of proteins involved in 
DNA repair, cell cycle arrest, and even anti-apoptotic genes such as Bcl-xL[142], continual 
p53 activation would cause the expression of pro-apoptotic genes like Bax [143] and Noxa 
[144] at the same time. If the DNA damage is repaired, and modifications of p53 manage to 
inactivate p53 in time, the cell cycle resumes and apoptosis is halted i.e. the cell lives. 
However, should the damage be too severe, continual expression of pro-apoptotic proteins 
would have caused the balance to be tipped towards apoptosis. As a result, apoptosis ensues 
and the cell carrying the irreparable mutation is removed.  
 In summary, this delicate balance between the various pathways in a normal cell is 
held in place by its ability to regulate these pathways in response to various cellular 
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conditions. However, when certain genes in the pathways are mutated, the ability to maintain 
such a balance is lost, which could then result in oncogenic transformation and cancer.  
 
1.4 p53 in Cancer 
 
 With p53 playing such important roles in controlling cell survival and apoptosis, it is 
not surprising that mutation of such a gene would have disastrous consequences. In fact, 
throughout the 30 years of research on p53, it is now common knowledge that 50% of the 
human cancers contain mutations in the p53 gene, while the rest of the cancers have 
mutations in genes that directly or indirectly affects the functions of p53.  
 
1.4.1 The “Trends” of p53 Mutation in Cancer 
 
Mutated p53 was found to correlate with the inability to induce apoptosis, with 
different p53 mutants conferring different degree of tumorigenesis [145,146]. From as early 
as 1985, the relationship between p53 mutation and cancer had been hypothesised. Le Beau‟s 
study [147] of acute promyelocytic leukaemia (APL) showed that the p53 gene located on 
chromosome 17 was translocated to chromosome 22 in patients suffering from APL.  In 
1989, Bodmer [148] found that mutations in p53 gene occurred in 50% or more of colorectal 
carcinomas. By 1991, a specific mutation has been linked to carcinogenesis. Hsu [149] and 
Bressac [150] found that a G to T substitution (causing an amino acid change from glycine to 
serine at codon 249) was prevalent in patients suffering from hepatocellular carcinoma 
(HCC) in China and South Africa.  Hence, it was suggested by both groups that this mutation 
could be the factor that resulted in the carcinogenesis of HCC. Subsequently, increasing 
number of groups started focusing on a correlation between p53 mutation and 
diseases/cancer, with the first review connecting p53 mutation and cancer being published in 
1991 [151].  
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B) 
 
 
Figure 1.5. Database compilations showing the A) distribution of mutation and B) the prevalence of p53 
mutation in tumours[152].  
 
The International Agency for Research on Cancer (IARC) website on p53 is a 
database which consolidates and compiles the gene variations and mutations found in human 
and tumour samples [152]. The data are compiled from the peer-reviewed literature and from 
generalist databases. The database shows that to date, the cancer with the most number of 
different p53 mutations is the colorectal cancer, followed closely by the respiratory system 
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and breast cancer (Figure 1.5A). However, the cancer that contains tumours with the highest 
percentage of p53 mutation is ovarian cancer, with a prevalence level at 47.3% (Figure 1.5B).   
 
A) 
 
  
B) 
 
 
Figure 1.6. Diagram showing the distribution of the type of mutations found in p53 from A) somatic 
mutations and B) germline mutations[152].  
 
Many forms of mutation can be found in the p53 gene. Deletion [153,154] or 
frameshift mutations [155,156] lead to the complete abrogation of p53 activities, while 
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translocation of the p53 gene [147], and point/missense mutations [157-160], result in the 
production of full-length p53 but with altered functions.  Interestingly, almost 74% of the 
mutations in p53 are missense mutations, that result in the synthesis of functionally defective 
p53 proteins [152,161] (see also Figure 1.6A). 
 
1.4.2 The Distribution of Mutation within p53 
 
As 74% of the mutations in p53 are missense mutation, it had garnered a lot of 
attention from researchers in a bid to characterize and profile the missense mutations found in 
various types of cancer. Putting the data together, it is obvious that most of the mutations 
occur within the DBD (residues 93-292) [152,162] (Figure 1.7A). A closer look at the data 
shows that mutations at certain residues are more frequent than the others, especially at 
residues 175, 248 and 273. These residues have been termed “hot-spot” mutations [163,164].  
Figure 1.7A depicts the distribution of the hot-spot residues found in cancers derived 
from somatic mutation of p53. However, not all cancers related to p53 are from somatic 
mutations. In fact, there is a condition known as the Li-Fraumeni Syndrome (LFS), in which 
individuals develop cancer as a result of a germline mutation in p53.    
LFS was first described and named after the discoverer in 1988 who investigated a 
family of 151 blood relatives found to develop cancers such as bone cancers, brain tumours 
and leukaemia before the age of 45 years [165].  The development of these cancers was later 
attributed to inherited germline p53 mutation [166]. Like the profile found in somatic 
mutations, most mutations in LFS are missense mutations. However, LFS also carries a 
higher percentage of p53 gene deletion (1.3% - Figure 1.6B) as compared to diseases from 
somatic mutations (0.1%). Large p53 gene deletions were found in several families studied 
for their genetics in the p53 gene and the development of cancers [167]. In any case, missense 
mutations still stand at a majority of 74.5%, a figure that is comparable to those arising from 
somatic mutations.  
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Figure 1.7. Profile of Codon Mutation Distribution in A) somatic mutation and B) germline 
mutation[152].   
 
The hot-spot mutations found in LFS are also relatively similar to those in somatic 
mutations, except for the arginine substitution at residue 337 (Figure 1.7B).  As mentioned 
during the discussion on the TAD of p53, a study on the development of ACC in children in 
Africa showed that 47% of the p53 mutation were due to an amino acid change from arginine 
to histidine at residue 337 (R337H) [168]. This data hence contribute slightly different profile 
between those found in germline mutations and those in somatic mutations.  
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1.4.3 Hypothesis of Action of p53 Mutants 
 
With such a high percentage of human cancers showing mutations in either p53 itself 
or in proteins that could affect its WT functions, studies were performed to explore the link 
between the mutations and the effect on prognosis. Indeed, tumours isolated from patients 
with p53 expression were usually associated with malignant progression, metastasis and poor 
prognosis across a wide range of cancers [169-172]. With such a high correlation between 
p53 mutation and poor survival rate, it is imperative to further study and understand the 
mechanism of mutant p53‟s impact on cellular functions, with the aim of developing 
therapeutic agents to reverse these adverse effects.  
 
1.4.3.1 Inhibition of Transactivation Function in Mutant p53 
 
With such a skewed distribution of mutation within the DBD of p53, a common 
hypothesis to explain the possible cause of these cancers is the inability of mutant p53 to bind 
to DNA, transactivate its target genes, and maintain homeostasis through the induction of cell 
cycle arrest and/or apoptosis. The profile of the hot-spot mutations seems to support this 
hypothesis. 
As mentioned earlier, residues 175, 273 and 248 are critical for the binding of p53 to 
DNA [173]. Studies on these mutants showed their reduced ability to transduce expression of 
genes such as p21 [173,174].  
Another phenomenon observed in human tumours with p53 mutations is the aberrant 
cytoplasmic localisation of p53 in some breast cancer and neuroblastomas [175,176]. Since 
p53 functions as a transcription factor, a nuclear localisation of p53 is essential in its 
transactivation function. Sequestered in the cytoplasm, p53 would be unable to carrying out 
this function. Interestingly, constitutive cytoplasmic localisation of WTp53 has also been 
reported in breast carcinomas [177], colorectal carcinomas [178], hepatocellular carcinomas 
[179] and retinoblastomas [180]. Moreover, the phenomenon has been linked to tumour 
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metastasis and poor survival of these patients [181,182]. These studies underscored the 
importance of transactivation by p53 in controlling cell proliferation and tumour progression. 
  
1.4.3.2 Gain-of-Function of Mutant p53 
 
 A common hypothesis is that oncogenesis in cancers with mutant p53 is caused by the 
reduced transactivation of p53 target genes. This hypothesis seemed logical in the presence of 
studies showing the relationship between reduced target gene expression levels and increased 
proliferation of tumour cells. Although it may seem adequate in explaining the phenomenon 
of tumours that habour mutant p53, it failed to explain the many concurrent findings of the 
overexpression of these mutant p53 proteins. So the question here is why is there a need for 
these tumour cells to overexpress mutant p53, when the missense mutations apparently are 
sufficient in impairing the functions of p53? All these seem to favour the hypothesis 
suggesting the possible gain-of-function (GOF) of p53 in eliciting oncogenic transformation. 
 One possible GOF mechanism involves the dominant negative effect that mutant p53 
exerts over the WT counterpart. In a study by Brachmann [183], mutant p53 was found to 
form tetramers with wild-type p53. As mentioned above, the mutations in these mutants 
usually interfere with their DNA-binding and transactivation activity. The heteromers forms 
between the WT and mutant p53 hence impaired the transcriptional activities of WTp53 as 
well.  
Supporting this hypothesis is evidence from several laboratories [184] which were 
investigating the post-translational modifications of mutant p53. The results showed that 
mutant p53 from tumour samples exhibited hyperphosphorylation at serine 392 [184-187]. 
Matsumoto [188] later found that hyperphosphorylation at serine 392 coincided with loss of 
DNA-binding and transactivation functions in these mutants. Since phosphorylation of 
WTp53 at serine 392 was found to stabilize and activate expression of genes [189], the 
hyperphosphorylation of serine 392 was proposed to produce a hyper-stable mutant p53, 
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which can hetero-oligomerise with its WT counterpart, thus preventing the proper functioning 
of WTp53. While it has yet to be proven that mutant p53 hyperphosphorylated at serine 392 
indeed exerts a dominant-negative effect over WTp53, poor prognosis was found to correlate 
very well with this phenomenon [186].  In addition, oligomerisation of WT and serine 392 
mutant p53 was found to exhibit a significantly reduced dissociation constant [190]. The 
formation of such stable oligomers could prevent functional WTp53 from performing its pro-
apoptotic activities. Further evidence to support the dominant negative GOF hypothesis came 
from another study, where mutant p53 was able to induce WTp53 proteins to adopt a mutant 
conformation, thereby affecting the latter‟s functions [191].  
Besides impairment of the inherent WT function, some studies showed that mutant 
p53 were able to transactivate new target genes, such as multidrug resistance gene (MDR1), 
found to be expressed in human cancer cells under the action of mutant p53. The 
overexpression of MDR1 confers resistance to cytotoxic drugs in these tumour cells [192]. C-
myc, an oncogene found to induce immortalization through desensitization of contact 
inhibition of growth, is also another target gene of mutant p53 [193,194]. In addition, mutant 
p53 was also found to transactivate BAG-1, an anti-apoptotic protein that inhibits the action 
of proapoptotic proteins Bcl-2 and Bcl-xL [195]. The combination of target genes induced by 
mutant p53 thus act to prevent apoptosis while promoting cell division at the same time, 
contributing to the oncogenic malignancy.  
The GOF of mutant p53 are not restricted to its transactivation properties alone. 
Studies have demonstrated that mutant p53 could inhibit process such as autophagy 
[196,197]. As discussed earlier, autophagy is a normal cellular function aimed at removing 
damaged proteins and organelles, thus facilitating the recycling of catabolites. Inhibition of 
autophagy by cytoplasmic p53 mutants could contribute to tumorigenesis by inhibiting the 
removal of damaged cellular organelles.  
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 In summary, the mere presence of mutant p53 is no longer adequate in explaining the 
more aggressive nature of tumour cells that possess these mutant proteins.  Many studies 
have demonstrated the “potency” of mutant p53 in oncogenesis by transfecting the genes for 
several mutant p53 into p53-null cells. Expression of mutant p53 in these cells have been 
shown to enhance “plating efficiency in agar cell culture”, “tumourigenic potential in nude 
mice” and “lymphohaematopoietic metastatic potential and tissue invasiveness” [198] while 
silencing of endogenous mutant p53 in cancer cell lines led to decreased cell proliferation, 
tumourigenicity and drug resistance [199]. These studies suggest a strong correlation between 
p53 overexpression and tumour formation [200]. Hence, it is increasingly noted that these 
p53 mutants may actively enhance, rather than contribute passively, to the survival of tumour 
cells.  
 
1.5 Therapies Targeting p53 
 
 Since p53 mutation is highly prevalent in cancer, numerous studies were undertaken 
to discover ways to reverse the effects of the mutation. The knowledge derived will thus 
bring us a step closer to helping the multitudes of people suffering from cancer caused by 
dysfunctional p53. 
 
1.5.1 Reintroducing Functional p53 
 
 Considering the fact that the normal p53 functions are lost in most cancer, a way to 
reverse this effect is to introduce a functional p53 gene into the genome. Encouraging results 
were shown in experiments involving the knock-in of functional p53 gene into mouse 
genome. In both studies, restoring endogenous p53 expression led to increased apoptosis and 
reduced tumour development [201,202].   
Even before these studies were published, clinical trials involving the introduction of 
a functional p53 gene into human subjects were already ongoing. Adenovirus modified to 
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contain a p53 gene was tested in patients suffering from recurrent glioma and non-small cell 
lung cancer among others. These trials yielded relatively promising results, whether used 
alone or in conjunction with chemo- or radiotherapy, with a slight majority of the patients 
showing partial to full regression of the disease [203-205]. As more of such studies are 
underway, progresses in this strategy is promising, with some trials already in Phase II 
[206,207]. Interestingly, p53 gene therapy is an approved medicine in China. 
 
1.5.2 Activation of Endogenous p53 
 
 As mentioned earlier, most p53 related cancers possess p53 in the tumours, be it WT 
or mutant. Instead of trying to make these tumour cells express functional p53 through the 
introduction of the gene into the cell genome, another strategy is to try to reactivate the p53 
proteins that already exist within the cells. 
 A method that was attempted involved the induction of p53 tetramerisation using 
pAb421, an antibody that recognizes an epitope that is found in some mutant p53. Use of this 
antibody allosterically activate sequence-specific DNA-binding by p53 [208,209]. No further 
progress has been reported for this potential treatment so far, possibly due to the difficulties 
in ensuring effective deliverance of large antibody protein into the cells. 
 With the elucidation of p53 protein structures, it became easier to study the interaction 
of p53 and other molecules using computer modelling. As such, small molecules can be 
designed to bind to mutant p53 and induce conformational change. Aided by the advances in 
molecular techniques and high throughput assays, large scale screening of small molecules 
capable of restoring WT conformation to the mutant p53 took flight, resulting in the 
discovery of PRIMA-1 [210]. PRIMA-1 was found to induce apoptosis in cells through the 
transactivation of Bax [211]. Currently, PRIMA-1 is in Phase II of clinical test [212].    
 Many similar studies are currently ongoing to identify other molecules which act like 
PRIMA-1. One advantage in using small molecules is that they can be designed for greater 
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cell permeability. Another advantage is that it holds the promise of being mutant specific 
through the optimisation of specific molecules, thus producing a whole spectrum of 
derivatives which can specifically bind and change the conformation of the various p53 
mutants found in different human cancers.    
 
1.5.3 Drugs Targeting the Negative Regulator of p53 
 
 Molecules that activate mutant p53 do so mainly by inducing a change in the 
conformation from mutant to WT, hence restoring its transactivation function. However, how 
would such molecules work on cancers habouring p53 with WT conformation? The answer 
lies in targeting the negative regulator of p53, MDM2. Currently, drugs that are either in 
clinical trials or already approved, work by disturbing the binding of WTp53 to MDM2, 
hence preventing degradation of the p53 proteins for pro-apoptotic functions. 
 A drug that is currently in Phase I testing is Nutlin [213]. The drug works by binding 
MDM2 at its p53 binding site. Nutlin was found to induce the accumulation and activation of 
p53 in both normal and cancer cells, and could lead to inhibition of tumour growth [214,215]. 
Another drug that works almost similarly is Actinomycin-D. Actinomycin-D inhibits p53-
MDM2 binding indirectly by disturbing ribosomal biogenesis, resulting in the release of 
ribosomal protein L11. L11 then binds to MDM2, leading to the stabilization and activation 
of p53 [216]. Actinomycin-D, at low doses, act like nutlin to induce cell death [217,218].  
 While nutlin and Actinomycin-D holds promise for cancers which harbour WTp53, it 
may not be effective when used on cancers with cytoplasmic localised WTp53. For such 
cancer cells, inhibition of MDM2 and MDMX may not disrupt the possible cytoplasmic GOF 
of this subset of p53 protein. Hence, more work needs to be done to research on the 
mechanism of GOF in these cancers and determine how the cytoplasmic function can be 
inactivated. 
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1.6 Objective of this Study  
 
The detection of mutant p53 being overexpressed in cancer is indeed an intriguing 
phenomenon. Despite the fact that most of the mutant protein remain localised in the nucleus, 
there are many observations that many tumours of diverse histological origins including the 
prostate cancer cell line, colorectal carcinoma and germ cell tumours [219,220] possess high 
levels cytoplasmically localised p53 (both WT and mutant). Several of these tumours with 
mislocalised p53 protein have been associated with greater survival and radio- and chemo-
resistance. Clearly, there are reasons to suspect that p53, particularly those ectopically 
concentrated in the cytoplasm, may aid the evasion of apoptosis via means unknown thus far. 
As discussed earlier, a commonly accepted hypothesis to explain the lack of apoptosis 
and chemotherapeutic resistance of such tumour cells include reduced transactivation, 
induction of new target genes that include resistance to drugs, and inhibition of autophagy. 
However, shouldn‟t the presence of WT or mutant p53 in the cytoplasm be able to induce 
apoptosis via direct activation of Bax and Bak directly? So why are these tumour cells not 
dying via apoptosis?  
Not discounting the fact that all the proposed mechanism of GOF could contribute to 
tumorigenesis, the idea that p53 may possess novel roles in inhibiting cell death should also 
be explored. A strong motivation comes from the fact that elevated p53 in the cytoplasm and 
Bax expression was not able to induce apoptosis in cells. Studies have shown that the 
transactivation of Bax was not sufficient to control cellular growth [221] and on the contrary, 
overexpression of Bax was instead associated with poor prognosis in patients suffering from 
non-small-cell lung cancer [222]. Questions thus arise as to whether p53 functions to inhibit 
the apoptotic process downstream of Bax activation, and what the targets of p53‟s 
“inhibitory” action are likely to be. 
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To answer the above questions, this study aims to elucidate the possible effect of p53 
on caspases, and overall cell survival. The hypothesis undertaken in this study is that p53 
inhibits apoptosis via the interference of the caspase signalling pathways, thereby prevents 
the activation of downstream signalling process and consequently helps in averting death of 
these tumour cells. 
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Chapter 2 
 
Materials and Methods 
 
 
2.1 Construction of WTp53 Encoding Plasmids 
 
 WTp53 gene was cloned into the expression vector pET-32b (Novagen, EMD 
Chemicals, USA) and mammalian expression vector pX40-HA-GFP (a kind gift from Prof 
Low Boon Chuan, NUS [223]). Primers were designed to the N-terminus and C-terminus of 
WTp53 using gene sequence from IARC Tp53 Database [152].  
 
WTp53 Forward primer: 5‟ – ATG GAG GAG CCG CAG TCA GA – 3‟ 
WTp53 Reverse primer: 5‟ – TCA GTC TGA GTC AGG CCC TT – 3‟ 
 
WTp53 were amplified using PCR in 1x AMV buffer, 1mM MgSO4, 10mM dNTP, 
0.7mM primers and 2.5 units of Tfl polymerase (Promega, USA) for 25 cycles. The PCR 
product was resolved in 1% agarose gel and the PCR product was purified using the Gel 
Extraction Kit from Qiagen, Germany. The purified product was then ligated to pGem-T-
Easy (Promega, USA). The ligation mixture were transformed into MAX Efficiency® DH5α 
(Invitrogen, USA) and overnight cultures of the colonies were amplified overnight at 37
o
C in 
Luria-Bertani (LB)-broth containing 50µg/ml ampicillin. Plasmids from the overnight 
cultures were extracted using Qiagen miniprep kit (Qiagen, USA). Positive clones were 
checked using restriction digestion with NotI enzyme (Promega, USA). The approximately 
1.3kb product from the restriction digestion was resolved in 1% agarose gel and gel-
extracted, followed by a final cloning into the pET-32b plasmid. The positive clones were 
sequenced using the Big dye (Applied Biosystems, USA), to determine the presence of the 
WTp53 gene as well as integrity of the sequence.  
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To clone the WTp53 gene into the pXJ40-HA-GFP plasmid, a new forward primer 
was designed so that the inserted gene can be cloned and expressed in frame. An additional 
adenine was placed in the 5‟ of the forward primer: - 
WTp53 pXJ40-HA forward primer: 5‟ – AAT GGA GGA GCC GCA GTC AG – 3‟ 
 
The cloning steps into pXJ40-HA were the same as cloning into the pET-32b plasmid. 
Both plasmids containing the WTp53 gene were amplified in large amounts using the 
Maxiprep kit (Qiagen, USA) according to manufacturer‟s instructions. The concentrations of 
the plasmids were quantified using the NanoDrop machine (Thermo Scientific, USA). 
 
2.2 Construction of Mutant p53 Encoding Plasmids via Site-Directed Mutagenesis 
 
From the pET32b-WTp53 and pXJ40-HA-GFP-WTp53 plasmids, various mutants of 
the p53 were generated using site-directed mutagenesis. Primers that contain the desired 
mutation were designed: - 
 
D42Y Forward Primer: 5‟ – AGC AAT GGA T(T)A TTT GAT GCT – 3‟ 
D42Y Reverse Primer: 3‟ – TCG TTA CCT A(A)T  AAA CTA CGA – 5‟  
 
R175H Forward Primer: 5‟ – GTT GTG AGG C(A)C TGA CCC CAC– 3‟ 
R175H Reverse Primer: 3‟ – CAA CAC TCC G(T)G ACG GGG GTG – 5‟ 
 
R337H Forward Primer: 5‟ – GGG CGT GAG C(A)C TTC GAG ATG – 3‟ 
R337H Reverse Primer: 5‟ – CCC GCA CTC G(T)G AAG CTC TAC – 3‟ 
 
 
pET-His-WTp53 or pXJ40-HA-GFP-WTp53 were added as templates to a mixture of 
1x pfu reaction buffer, 10mM dNTP mix, 0.7mM of the above overlapping primers and 0.8 
units pfu turbo polymerase (Stratagene, USA).  
The PCR reactions were transformed into MAX Efficiency® DH5α (Invitrogen, 
USA). Multiple colonies were picked, cultured overnight before plasmids were isolated. The 
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plasmids were sequenced to determine the presence of the point mutation, and also the 
integrity of the rest of the gene.  Positive clones were amplified in large amounts using the 
Maxiprep kit (Qiagen, USA) according to manufacturer‟s instructions. The concentrations of 
the plasmids were quantified using nanodrop machine.  
 
2.3 Preparation of Recombinant p53 
 
Polyhistidine-tagged p53 (WT, D42Y, and R175H) in pET vector (obtained in section 
2.4) and pET-32b-p53
R337H
 (contributed by Phua [224]) was transformed into Escherichia 
coli BL21 Star
TM 
(DE3) pLysS bacteria (Novagen, USA). Cultures were grown in LB-broth 
containing 50μg/ml ampicillin at 37оC till exponential phase and induced at 0.1 M isopropyl-
1-thio-ß-D-galactopyranoside (IPTG) overnight at 30
о
C.  
Bacteria were harvested by centrifugation, resuspended in binding buffer (0.5M NaCl, 
20mM Tris-HCl and 5mM imidazole, 1% protease inhibitor and 10 μl (per litre of bacteria 
culture) Benzonase, pH 7.9) followed by sonication at 40% amplitude for 4 min. Sonicated 
mixtures were centrifuged at 5500rpm for 15 min to collect a pellet containing inclusion 
bodies and cellular debris. This pellet was washed thrice by resuspension in binding buffer, 
sonication at 40% amplitude for 4 min and centrifugation at 5500rpm for 15 min. After the 
final sonication and centrifugation, the pellet was resuspended in 6M urea (dissolved in 
binding buffer) and incubated on ice for 1 hour to dissolve and denature the proteins in the 
inclusion bodies. Insoluble materials were then removed by centrifugation at 5500rpm for 30 
min. Supernatant collected containing solubilised p53 as the dominant protein species was 
verified by 12% SDS-PAGE gel and Coomassie staining and were either stored at 4°C or 
proceeded with protein renaturation.  
Recombinant p53 (wild-type and mutant) were renatured according to Bell [225]. In 
brief, solubilised p53 was diluted to 10μg/ml in refolding buffer (50mM tetrasodium 
diphosphate, 1M L-arginine, 2mM DTT, 0.2nM ZnCl2, pH 8.0) and incubated overnight at 
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15°C. The solution was dialysed for 48 hours against dialysis buffer (50mM tetrasodium 
diphosphate, 4mM DTT, 5% (v/v) glycerol, pH 8) at 4°C. Dialysed samples were centrifuged 
at 5500rpm for 30min at 4°C to remove aggregates and concentrated using Vivaspin 
centrifugal concentrators (Sartorius, France) to a final protein concentration of 0.5μg/μl. The 
integrity of the recombinant p53 in the dialysed sample was reassessed by SDS-PAGE. 
The 21kDa His-S-Thioredoxin tag (hereby referred to as HST-tag) expressed by the 
empty plasmid of pET-32b were also produced, refolded and renatured to perform as a 
negative control. 
 
2.4 Glutaraldehyde Test for Tetramerisation in p53 
 
 10µg of the various refolded recombinant p53 were used for each test condition. 
0.02% and 0.1% glutaraldehyde were used to induce cross-linking in the recombinant 
proteins for 1 minute at room temperature. 0% glutaraldehyde was used as controls. The 
reactions were stopped using equal volume of 1M Tris-HCl pH 7.4. The same conditions 
were used to induce cross-linking for 10µg of bovine serum albumin (BSA) as an additional 
negative control. 
 
2.5 Cell Culture 
 
Human embryonic kidney (HEK) 293T [226,227] and HEK293 cells [228] (both 
generous gifts from Dr Low Boon Chuan, NUS), A2780 (ECACC, United Kingdom), and 
PEO1 and PEO4 [229] were cultured in RPMI medium supplemented with 10% foetal bovine 
serum (FBS) and 1% penicillin/streptomycin. Human large cell lung carcinoma H1299 p53
-/-
 
(ATCC, USA) were cultured in DMEM supplemented with 10% FBS and 1% penicillin-
streptomycin. Human colon tumour (HCT)-116 p53
-/-
 [230] were cultured in McCoy 5A 
medium supplemented with 10% FBS and 1% penicillin-streptomycin. 
 
Chee Lai Yuen  
53 
 
 
2.6 Preparation of S100 Cytosolic Cell-Free Extracts  
 
To isolate cytosolic fractions of cells, cells were harvested, washed twice in PBS and 
resuspended in ice-cold IDP buffer (20mM Hepes-KOH, pH 7.5, 10mM KCl, 1.5mM MgCl2, 
1mM EDTA, 1mM EGTA, 1% protease inhibitor cocktail [AEBSF-Hydrochloride, Aprotinin, 
E-64-Protease Inhibitor, EDTA-Disodium, Leupeptin-Hemisulfate] and 3mM DTT). After 
incubation on ice for 10 min, the cells were disrupted by Dounce homogenizing for 25 times 
in a Wheaton Dounce homogenizer with a tight pestle. Cells extracts were directly 
centrifuged at 14,000rpm in a Beckam Optima TLX-100 ultracentrifuge for 20min at 4
o
C. 
The resulting supernatants (S100 cell-free extracts) were collected.  
 
2.7 Preparation of Dyna-beads® coupled to p53 Antibodies 
 
 1mg of M-280 Tosylactivated Dyna-beads® (Invitrogen, USA) were coupled to 10μg 
of anti-p53 antibodies (DO-1 (10 μg) and pAb240 (5 μg), both from Santa Cruz, USA; 
pAb421 (5 μg) from Calbiochem, USA) according to manufacturer‟s protocol. 20 μg of anti-
HA antibodies (Santa Cruz, USA) were coupled to the beads as control.  
 
2.8 Addition of recombinant proteins and in vitro Caspase Activation  
 
S100 extracts of HEK293, HCT-116 p53
-/-
 and A2780 cells were obtained as 
described in Section 2.5.  Dialysis buffer, 0.1μM and 0.3μM of the various recombinant p53 
produced in Section 2.3 were added separately into different portions of the S100 extracts. In 
addition, 0.3μM of recombinant GST (a kind gift from Baidah Bte Ahmad, NUS), GST-
tagged WTp53 (Santa Cruz, USA) and S-tagged recombinant WT Nucleophosmin (NPM) (a 
kind gift from Tan Ban Xiong, NUS) were added to the S100 extracts from the various cell 
lines as additional controls. To per mg of protein in the HEK293 extract, 20nM dATP and 
4μg of cytochrome-c were added to induce in vitro caspase activation, 20nM dATP and 12 μg 
of cytochrome-c for HCT-116 p53
-/-
 lysates and 30nM dATP and 15µg of cytochrome-c for 
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A2780 lysates to do the same. Samples were incubated in the dark at room temperature for 1 
hour before the reactions were stopped by freezing at -20
o
C. Profile of p53, caspase-3 and -9, 
PARP, cytochrome-c and GAPDH in the samples was analyzed subsequently by Western blot 
(described in Section 2.12). 
 
2.9 Immunodepletion and in vitro Caspase Activation 
 
HEK293T and A2780 cells, harvested and lysed to obtain S100 cytosolic cell-free 
extracts, were incubated with the Dyna-beads® obtained from Section 2.6 for 2 hours on a 
rotator at 4°C. The lysates were removed from the magnetic beads and the appropriate 
amount of dATP and cytochrome-c were added to induce caspase activation. Samples were 
incubated in the dark for 15min and 1 hour at room temperate before storage at -20°C. 
Activation of various caspases was analyzed by Western blot subsequently.  
 
2.10 Transfection and in vitro Caspase Activation 
 
H1299 p53
-/- 
cells, cultured to approximately 70% confluency in 10-cm plates, were 
transfected with various amounts of pXJ40-HA-GFP-WTp53/ pXJ40-HA-GFP-p53
D42Y
/ 
pXJ40-HA-GFP-p53
R175H
 / pXJ40-HA-GFP-p53
R337H
 using Lipofectamine-2000 (Invitrogen, 
USA). Cells were harvested 6 hours post-transfection and lysed to obtain S100 cell-free 
extracts. Caspase cleavage was then induced by adding the appropriate dATP and 
cytochrome-c. Caspase-9 activity was measured using 200µM of LEHD-pNA substrate 
(BioVision, USA) and the yield of the coloured pNA product was measured at 405nm at 2 
minute interval over a 12-hour period.. Efficiency of p53 transfection was analyzed by 
Western blot subsequently. 
 
2.11 Knockdown of p53 and in vivo Caspase Activation 
 
PEO1, PEO4 and A2780 were cultured to approximately 70% confluency in optical 
and clear 96-well plates. Transfection were performed using 50nM of control siRNA and 
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siRNA against p53 (Cell Signal, USA) with 0.125μl of DharmaFECT transfection reagent 
(Dharmacon, USA) per well. Cells were incubated overnight before the addition of 25μM of 
cisplatin for a further 24 hours. Control cells were treated with equivalent volume of PBS. 
Cells cultured in clear 96-well plate were measured for cell density using the 
Sulphorhodamine B (SRB) assay. Briefly, cells were fixed in ice-cold 10% (wt/vol) 
trichloroacetic acid for 1 hour at 4
o
C. Cells were then washed with water and air dried before 
staining with 0.057% (wt/vol) SRB solution for 30 minutes at room temperature. Stained 
cells were then washed four times with 1% (vol/vol) acetic acid. Finally, the stained cells 
were solubilised with 10mM Tris base solution (pH10.5) for 30 minutes before reading the 
plate at 510nm. 
Cells cultured in optical plate were subjected to Caspase-Glow
TM
-9 (Promega, USA) 
assay according to manufacturer‟s instructions. After 30 minutes incubation with Caspase-
Glow
®
-9 substrate, the activity of caspase-9 were measured with a fluorimeter at 535nm and 
normalized against cell density obtained from the SRB assay described above. 
 
2.12 Knockdown of p53 and in vitro Caspase Activation 
 
 HEK293 and A2780 cells were cultured to approximately 70% confluency in 10-cm 
culture plates and p53 were knockdown were done as described in Section 2.9. For HEK293 
cells, S100 lysates were obtained after 48 hours post-transfection, while for A2780, S100 
lysates were obtained after 24 hours post-transfection. Caspase activation was then induced 
using the appropriate amount of dATP and cytochrome-c and analyzed using Western blot. 
 
2.13 Detection of Interacting Partner of p53 using Immunoprecipitation 
 
 S100 lysates were obtained from HEK293 cells in IDP buffer containing 10mM DTT 
and caspase activation were induced using the appropriate amounts of dATP and cytochrome-
c. The lysates containing the cleaved caspases were incubated with Dyna-beads® coupled to 
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either anti-HA or anti-p53 antibodies for 1 hour at room temperature. After the incubation, 
the lysates were removed and the beads were washed with the same IDP buffer. The bound 
p53 were eluted with Elution Buffer from Seize IP Kit (Pierce, USA). The eluent were 
analyzed for presence of p53 and caspase-9 using Western blot. 
 
2.14 Detection of Interacting Partner of p53 using Immunoprecipitation and Cross-linking 
 
S100 lysates were obtained from HEK293 cells in IDP buffer containing 10mM DTT 
and caspase activation were induced using the appropriate amounts of dATP and cytochrome-
c. The lysates containing the cleaved caspases were incubated with 0.1µM of HST-tag or 
HST-tagged p53 proteins for 15 minutes at room temperature with agitation. 30µl of nickel 
beads (Qiagen, USA) were added to each fraction and incubated further 15 minutes with 
agitation. Nickel beads were pelleted at 1000rpm and lysates were removed. The nickel beads 
were washed once with PBS. 100µl of PBS were then added to the beads. 10mM of nickel 
acetate were added to the solution and incubated for 10 minutes at room temperature, 
followed by 30mM of magnesium monoperoxyphtaleic acid (MMPP) for a further 6 minutes. 
The beads were then washed thrice with PBS and analyzed for presence of p53 and caspase-9 
using Western blot. 
 
2.15 Electrophoresis and Coomassie Staining 
 
 Recombinant p53 from Section 2.3 were mixed with Laemmli‟s loading dye, boiled 
for 5 min at 95°C and subjected to 12% SDS-PAGE at 100V for 1.5h. The gels were stained 
by Coomassie brilliant blue. 
 Recombinant p53 from Section 2.4 were mixed with Laemmli‟s loading dye, boiled 
for 5 min at 95°C and subjected to 4-12% gradient SDS-PAGE at 100V for 1.5h. The gels 
were stained by Coomassie brilliant blue for analysis.  
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2.16 Electrophoresis and Western Blot Analysis 
 
Equal amounts of proteins were mixed with Laemmli‟s loading dye, boiled for 5 min 
at 95°C and subjected to 12% SDS-PAGE at 100V for 1.5h. Separated proteins were 
electroblotted onto nitrocellulose membranes at 15V for 30 min followed by blocking with 
3% skimmed milk for 15min. Specific proteins were probed with anti-p53 DO1 (Santa Cruz, 
USA, 1:3000), anti-caspases 3, 6, 8, 9 (Cell Signalling Technology, USA, 1:2000), anti-S-
tag-HRP (Bethyl Laboratories, USA, 1:2000) anti-cytochrome c (Pharmingen, USA, 1:2000), 
anti-GAPDH (Ambion, USA, 1:10000) or anti-PARP (Santa Cruz, USA, 1:2000) overnight. 
Membranes were rinsed with TBS-T and incubated with corresponding polyclonal anti-rabbit 
or anti-mouse horseradish peroxidase-conjugated secondary antibodies (1:1000 to 1:3000) for 
1h. Following 1h incubation, membranes were rinsed with TBS-T and last wash were done in 
TBS. Bound antibodies on membranes were detected using pico or femto enhanced 
chemiluminescence kit (Pierce, USA).  
 
2.17 Electrophoresis and Far Western Blot Analysis 
 
 Recombinant caspase-9 was first expressed using the in vitro translation system 
(Pierce, USA) with 0.5µg of pET-32b-WT-caspase-9 (addgene, USA). 20µg of S100 lysates 
of H1299 p53
-/-
 cells transfected with 2.5µg of pXJ40-HA-GFP-WTp53 from Section 2.10 
were used as a Western blot control. 0.5mg of HST-tag expressed by pET-32b plasmids were 
used as a negative control. 15ng of active caspase-9 (Calbiochem, USA) was used as the prey 
protein, while 1µl of the IVT reaction described above were used also as a negative control as 
it contains high concentration of the procaspase-9 protein. The proteins were mixed with 
Laemmli‟s loading dye, boiled for 5 min at 95°C and subjected to 12% SDS-PAGE at 100V 
for 1.5h. Separated proteins were electroblotted onto nitrocellulose membranes at 15V for 30 
min. Based on the protocol by Wu [231], proteins on the membrane were refolded by 
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incubating the blots with AC buffer (10% glycerol, 0.1M NaCl, 20mM Tris-HCl-pH 7.4, 
1mM EDTA, 0.1% Tween-20, 10mM DTT, 2% milk) containing 6M guanidine-HCl for 30 
minutes, followed by AC buffer with 3M guanidine-HCl for 30 minutes, then AC buffer with 
1M guanidine-HCl for 30 minutes. All of the above incubations were at room temperature. 
Subsequently, the blots were incubated at 4
o
C in AC buffer with 0.1M guanidine-HCl for 30 
minutes and finally in AC buffer containing no guanidine-HCl overnight at 4
o
C. The blots 
were then blocked with TBS-T containing 5% milk for 1 hour at room temperature. 0.1µM of 
the HST-tag and the various recombinant HST-tagged-p53 were incubated with the blots 
separately in the interaction buffer (contents of the interaction buffer was similar to AC 
buffer except that 0.5mM EDTA were used) for 1 hour at room temperature. After 
incubation, the buffer containing the proteins was removed. The blots were washed and the 
bound p53 were detected using DO1-HRP (Santa Cruz, USA) and and S-tag-HRP antibodies 
(Bethyl Laboratories, USA) at 1:2000 dilution in TBS-T containing 1.5% milk. For blots that 
were subjected to cross-linking reactions, after the solutions containing the proteins were 
removed, 10ml of PBS were added to each blot. Cross-linking reactions were initiated with 
10mM of nickel acetate for 10 minutes, followed by 30mM of MMPP for a further 6 minutes. 
The blots were finally washed and bound p53 were detected using DO1-HRP and S-tag-HRP 
antibodies (Santa Cruz, USA) at 1:1500 dilution in TBS-T containing 1.5% milk. 
 
2.18 Kinetics of p53-Dependent Inhibition of Caspase Activity 
 
 The various recombinant HST-tagged-p53 were incubated with 2.8µM of active 
recombinant caspase-9, 20nM of active recombinant caspase-3, and 25nM of active 
recombinant caspase-6 (all recombinant proteins are from Calbiochem, USA) in 1x Reaction 
Buffer containing 10mM DTT (BioVision, USA). A positive control was set up with no 
addition of any recombinant protein while a negative control was set up with the addition of 
the highest concentration of the HST-tag in the particular set of experiment. 200µM of 
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LEHD-pNA substrate (for caspase-9), DEVD-pNA substrate (for caspase-3) and VEID-pNA 
substrate (for caspase-6) were added and the yields of the coloured pNA product were 
measured at 405nm at 2 minute interval over a 1-hour period.   
 
2.19 Survival of Cells Transfected with various p53 in Cisplatin  
 
 HCT-116 p53
-/-
 cells were first cultured in 6-well plates to approximately 60% 
confluency. Various dosages of cisplatin were then added to the medium and cells were 
exposed to the drug for 72 hours. PBS was added as the control. After 72 hours, dead cells 
were removed and the adherent cells were collected and lysed in Total Cell Lysis buffer 
(100mM HEPES pH 7.5, 5mM MgCl2, 150mM NaCl, 1mM EDTA, 1% Triton X-100 + 1% 
protease inhibitor cocktail [AEBSF-Hydrochloride, Aprotinin, E-64-Protease Inhibitor, EDTA-
Disodium, Leupeptin-Hemisulfate]) for 10 minutes on ice, and centrifuged at 14000rpm to 
remove the cell debris. The supernatants were collected as the total cell lysate. Profile of 
caspase-9 and PARP were then analyzed using Western blot.  
Subsequently, HCT-116 p53
-/-
 cells were cultured in 24-well plates to approximately 
40% confluency. 0.2µg of pXJ40-HA-GFP/pXJ40-HA-GFP-WTp53/ pXJ40-HA-GFP-
p53
D42Y
/ pXJ40-HA-GFP-p53
R175H
/ pXJ40-HA-GFP-p53
R337H
 were transfected into the cells 
using Lipofectamine 2000. At 4 hour post-transfection, cells were poisoned with 0.5mM 
cisplatin (Sigma-Aldrich, USA) with treatment with PBS as the control. This was considered 
as 0-hour. At 0-hour, cells were stained with 0.5µg/ml Hoechst-33342 (Sigma-Aldrich, USA) 
for 10 minutes. Cells were then washed twice with PBS to remove the dead cells. The cells 
were then viewed under Olympus inverted fluorescent microscope. Images of the GFP and 
Hoechst fluorescence were captured using the DP Controller software from Olympus. More 
images were captured subsequently at 24 hour interval after challenge with cisplatin. Finally, 
the fluorescence in the captured images were counted using ImageJ software. First, the 
percentage of the transfected cells in each well were calculated by expressing the amount of 
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transfected cells (GFP fluorescence) over the total number of cells in the well (Hoechst 
staining). The change in transfected cells between the PBS and cisplatin-challenged cells 
were next also expressed as a percentage. The percentages obtained at 0-hour for each p53 
variant and the GFP control was used as a reference point. The change in percentages of 
differences in transfected cells for each p53 variant and the GFP control over the 72-hour 
period were obtained to illustrate the survivability of the cells transfected with the various 
p53 plasmids. 
 
2.20 Cells Transfected with various p53 in Cisplatin and their Caspase-9 Activities  
 
 Similar to Section 2.15, HCT-116 p53
-/-
 cells were cultured in 24-well plates to 
approximately 40% confluency. 0.2µg of pXJ40-HA-GFP/pXJ40-HA-GFP-WTp53/ pXJ40-
HA-GFP-p53
D42Y
/ pXJ40-HA-GFP-p53
R175H
/ pXJ40-HA-GFP-p53
R337H
 were transfected into 
the cells using Lipofectamine 2000. At 4 hour post-transfection, cells were poisoned with 
0.5mM cisplatin (Sigma-Aldrich, USA) with treatment with PBS as the control. This was 
considered as 0-hour. At 72 hours post-transfection, 1µl of fluorescence caspase-9 substrate, 
Red-LEHD-FMK from the Caspase-9 Detection Kit (Calbiochem, Merck, Germany) were 
added to each well and incubated for 30 minutes. 10 minutes prior to end of assay, cells were 
stained with 0.5µg/ml Hoechst-33342 (Sigma-Aldrich, USA). At the end of the assay, cells 
were washed twice with Wash Solution to remove the dead cells and excess caspase-9 
substrate. Fluorescent images were captured as per Section 2.15. ImageJ was used as an 
imaging and counting tool. Cells that had both caspase-9 and GFP fluorescence were scored 
as a percentage over the total number of transfected cells (GFP fluorescence) for each well. 
This percentage was next used to calculate the change in correlation between the caspase-9 
and GFP fluorescence between the PBS and cisplatin-challenged cells for the GFP control 
and each p53 variant. Using GFP as the reference point, the change in correlation for each 
p53 variant was expressed as a percentage over GFP.  
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Chapter 3 – Results 
 
p53 and its Mutants Directly Inhibits  
caspase-9’s Activity 
 
3.1 Introduction 
 
The hypothesis of this study is that p53 inhibits apoptosis by interfering with the 
caspase signalling pathways, thereby preventing the activation of downstream caspase 
targets. This may in turn, increase the apoptotic threshold of cells, rendering them more 
susceptible to oncogenic transformation. Until recently, there has been no report of p53 as a 
direct inhibitor of any of the 14 known human caspases. Certain p53 mutants (p53
R175H
 and 
p53
R273H
) were associated with the downregulation of procaspase-3 and increased resistance 
to drug-induced apoptosis [232,233]. On the contrary, WTp53 was shown to lower the 
apoptotic threshold by inducing caspase-6 expression
 
[234]. The apparently paradoxical 
situation suggests that while WTp53 may serve to facilitate apoptosis, mutant p53 may 
conversely increase the apoptotic threshold through suppression of caspase gene expression. 
A more direct link between p53 and caspases was demonstrated in another study in which 
knockdown of p53 in human osteoblast cells resulted in heightened caspase activities [235]. 
Although such reports are far and few between, it certainly does not reduce the motivation to 
explore p53‟s relationship with caspases in greater detail. 
To fully understand how p53 and its various mutants may directly regulate caspase-
9‟s activity in the cell death signalling process, four p53 isoforms were chosen for this current 
investigation: (1) WTp53 (which serves as a control for comparison); (2) p53
D42Y
 (point 
mutation at the TAD region); (3) p53
R175H
 (point mutation at the TAD region); (4) p53
R337H
 
(point mutation at the TD region). By selecting point mutations that span different domains of 
the p53 protein, this study aims to investigate how mutations at the different domains may 
influence the protein‟s effects on caspases. Of note here, p53D42Y was chosen partly because 
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the mutant was reported in ovarian cancer patients [236], a cancer which this study will 
attempt to focus on. A more detailed introduction to this cancer is covered in Chapter 5. 
Meanwhile, p53
R175H
 mutant was chosen not only because the point mutation lies within the 
DBD, but also due to the fact that it is a structural mutant. This choice will further aid in 
determining a structural requirement for p53 in the regulation of caspase activities. Lastly, the 
fourth mutant p53
R337H
 was selected as the point mutation at the TD affects protein 
tetramerisation, an important feature responsible for its transactivation property. At the same 
time, the study of this mutant could reveal clues to its probable pathological role(s) in LFS.  
 
3.2 Results 
 
3.2.1 Production of Highly Purified Recombinant p53 that is Capable of Tetramer Formation  
 
 The various forms of recombinant p53 were produced and refolded according to 
protocol reported by Bell [225]. In order to examine the purity of the recombinant proteins 
produced, equal amount of lysates from each round of sonication were saved, separated in a 
SDS-PAGE gel and Coomassie-stained. As seen in Figure 3.1 (A & B), a band of 
approximately 74kDa, which corresponds to the size of recombinant p53 fused with the His-
S-Thioredoxin (HST) triple tags of approximately 21kDa, was isolated and purified.  
 To show that the recombinant p53 was refolded properly, the proteins were first 
assessed by Far-UV circular dichroism (CD). According to DiGiammarino [43], both WTp53 
and p53
R337H
 proteins exhibit the same CD spectrum. As expected, the CD data obtained for 
both proteins in this study were similar (Figure 3.1B), indicating that the proteins have been 
refolded properly.  
 Tegtmeyer [237] and Prives [238] reported that properly folded native murine and 
human p53 proteins were able to form tetramers. This forms the basis of the second test used 
to confirm if the recombinant p53 produced here was refolded correctly and was able to form 
tetramers. To do this, two concentrations of glutaraldehyde were used to induce cross-linking 
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between the monomers of the recombinant p53. As shown in Figure 3.1C, the various 
recombinant p53 forms were able to form tetramers (shown approximately at molecular 
weight of 300kDa). However, different degrees of tetramerisation were evident. WTp53 
tetramers were apparent at 0.02% glutaraldehyde, seen from the shift in bands from 74kDa to 
approximately 300kDa. The mutant p53 proteins however, showed a reduced concentration 
of tetramers since at the same concentration of glutaraldehyde, the monomeric p53 form was 
present. Among the mutant p53 proteins, D42Y and R175H showed similar behaviour with 
the monomer species only absent at the 0.1% glutaraldehyde and some evidence of dimers 
not seen with the WT protein. Meanwhile, the tetrammerisation mutant p53
R337H
 showed the 
lowest level of tetramers at all three concentration of gluteraldehyde used. BSA was used as a 
negative control. Although the band intensities of the protein shifted slightly upon exposure 
to glutaraldehyde, the changes were not significant (graph, Figure 3.1C).  The magnitude of 
the changes in the intensities of the monomeric species of the various p53 proteins are also 
displayed in the same graph. 
The cross-linking experiment here demonstrated the differential ability of the various 
p53 mutants to tetramerise, and this, in turn, correlates well to the known differential effects 
of the various point mutations on the structural integrity of the properly refolded protein.  The 
purified and properly folded recombinant p53 were thus used for further tests in this study. 
 
3.2.2 WT and Mutant Recombinant p53 Inhibit Caspase Activation 
 
 To investigate the hypothesis that p53 may inhibit caspase activity and activation, the 
recombinant p53 produced were added to S100 cytosolic fractions of HEK293 cells with 
endogenous WTp53. Apoptosis was initiated with the addition of cytochrome-c. In agreement 
with the hypothesis, inhibition of caspase cleavage was observed with the addition of the 
recombinant p53. Also, a dose-dependent inhibition of caspase cleavage was evident i.e. as 
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more recombinant p53 was added, the inhibition of caspase cleavage became more 
pronounced. The inhibition appeared to affect the caspase cascade upstream, with inhibition 
apparent on caspase-9, the most apical caspase to be activated upon cytochrome-c initiated 
apoptosis. As introduced in Section 1.2.5.1, caspases belong to a distinctive and highly 
conserved class of intracellular cysteine proteases. When activated by apoptotic signals, they 
are proteolytically cleaved at the aspartic acid residue into one large and one small subunit 
that assemble with each other to form enzymatically active heterotetramers [79]. The 
majority of the cleavage of caspase-9 occurs at the aspartic acid reside at position 315, 
generating two subunits of p35 and p12 [239]. Activation of caspase-3 occurs at the aspartic 
acid residue at position 175, producing two subunits of p20 and p11 [240]. The dimerization 
of p35 and p12 subunits forms the active unit of caspase-9 [241] while the dimerization of the 
p20 and p11 subunits forms the active unit of caspase-3 [242].  
As seen from Figure 3.2, the addition of the various recombinant p53 led to a decrease 
in the p37 and p35 bands, the active subunits of caspase-9, with the concurrent restoration of 
the non-active p46 procaspase band. The inhibition of caspase-9 cleavage affected the 
activation and cleavage of direct downstream targets such as caspase-3 and PARP. As 
caspase-6 and caspase-8 are also reported to participate in the caspase amplification loop 
[243-245], these two caspases were probed for their cleavage patterns. Both caspases showed 
either reduced or no activation, as compared to caspase-9 and caspase-3, which are direct 
downstream targets of cytochrome-c induced apoptosis, indicating that these caspases were 
too far downstream and therefore were not affected by the caspase activation cascade.  
To confirm this phenomenon, the experiment was repeated using S100 cytosolic 
fractions derived from HCT-116 p53
-/-
 cells. This was done to eliminate the possible 
interference by endogenous p53 which is present in the cytosolic extracts of HEK293 cells. 
The same inhibitory effects on the caspases were observed (Figure 3.3), indicating that the 
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results from the experiments with both cell line lysates were solely due to the addition of 
recombinant p53 and not the endogenous p53.  
In both experiments carried out with HEK293 and HCT-116 p53
-/-
 cell lysates, the 
proteins affected by the cytochrome-c-induced apoptosis were caspase-9, caspase-3 and 
PARP. Meanwhile, caspase-6 and caspase-8 were demonstrated to be too far downstream to 
be affected by the inhibitory action of p53. For this reason, the profiles of both caspases were 
omitted from further experiments. 
Although the results obtained using HEK293 and HCT-116 p53
-/-
 cells were 
encouraging, these two cell lines were artificially generated from existing cell lines either 
through adenovirus-induced transformation (HEK293) [246], or homologous recombination 
to disrupt the endogenous WTp53 gene (HCT-116 p53
+
/
+
 cells) [230]. To eliminate the 
possibility that these additional manipulations used in creating these cell lines could have an 
effect on the results obtained, the experiments were repeated using A2780, an ovarian cell 
line established directly from the tumour tissues of the ovaries that expresses WTp53.  
As shown in Figure 3.4, the addition of the various recombinant p53 proteins into the 
S100 lysates of A2780 were able to inhibit caspase-9, and the downstream proteins, similar to 
the effects found in both HEK293 and HCT-116 p53
-/-
. Hence in this unmanipulated tumour 
cell line, the addition of exogenous recombinant p53 was still able to inhibit caspase-9 
implying that the endogenous level of WTp53 in these cell extracts was not saturating for p53 
dependant inhibition of caspase activity. 
To further eliminate doubts about the inhibitory effect of the folded HST-p53 on 
caspase-9, a commercial source of active recombinant GST-tagged WTp53 was tested for its 
effect on caspase-9 in A2780 lysates induced to undergo caspase activation via the addition 
of recombinant cytochrome-c. Recombinant S-tagged nucleophosmin (NPM) was also 
included as a negative control as a recently published study by Leong [247] had demonstrated 
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its inhibitory effects on caspase-6 and caspase-8, but not on caspase-9 and caspase-3. As 
expected, only the tagged WTp53 were able to inhibit the cleavage of caspase-9 (Figure 3.5). 
One thing to note in this set of experiment is that, although the recombinant tagged p53 
proteins were able to inhibit caspase-9 cleavage, the inhibition of the downstream proteins 
such as PARP was not as pronounced as those seen in Figures 3.2 to 3.4. Therefore, this 
would require another study to explore if selective inhibition could be seen at earlier time 
points. 
 
3.2.3 In Vitro Depletion of Endogenous p53 Accelerates Caspase Activation 
 
Since it was demonstrated that the presence of increased amount of p53 resulted in the 
inhibition of caspase-9, the next set of experiments were performed to determine if removal 
of p53 could accelerate caspase-9 activation. Immunodepletion of endogenous p53 from cells 
at normal physiological conditions served to minimize any disturbance to the normal cellular 
activities and functions. Endogenous p53 was immunodepleted from the cytosolic fraction of 
HEK293T cell lysates prior to treatment with cytochrome-c. In agreement with the 
hypothesis, the partial removal of p53 led to increased caspase-9, caspase-3 and PARP 
cleavage, compared to the non-immunodepleted cell lysates in which the endogenous p53 
was still present (Figure 3.6). 
As introduced earlier, WTp53 expressed in HEK293T cells were presumed to have 
been inactivated by the T-antigen of SV40, which is constitutively expressed in this cell line 
[228,248]. To eliminate the possibility of the inactivated p53 could have any bearing on the 
final outcome, the experiment was repeated using the cytosolic fractions derived from A2780 
cells with functional WTp53. Indeed, the results obtained (Figure 3.7) were similar to those 
of HEK293T. Taken together, the results further supported the hypothesis that p53 may 
directly inhibit caspase activation. 
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3.2.4 Knockdown of p53 Accelerates Caspase Activation 
 
To investigate if the inhibitory effect occurs in an in vivo environment, p53 was either 
removed through siRNA-mediated knockdown of p53, or by overexpression of these various 
p53 forms in p53-null cells. With the assumption that the inhibition is targeted at caspase-9, 
cells from both the knockdown and overexpression experiments were harvested for their 
cytosolic fraction and cytochrome-c-induced caspase-9/caspase-3 cleavage were investigated 
using immunoblotting.  
In the knockdown experiments (Figures 3.8 and 3.9), reduction of endogenous p53 in 
both HEK293 cells and A2780 cells resulted in higher caspase-9, caspase-3 and PARP 
cleavage. Here, HEK293 cells were used instead of HEK293T cells. This is due to the fact 
that HEK293, which is isogenic to HEK293T cells, lack the expression of the T-antigen of 
SV40 [249]. A similar phenomenon was observed in both p53 knockdown experiment on 
HEK293 and p53 immunodepletion experiment on HEK293T cells. Therefore, the use of 
HEK293 cell line helped to substantiate that the results obtained from p53 immunodepletion 
experiment on HEK293T were indeed true. For A2780 cell line, an additional experiment 
was carried out which involved the measurement of caspase-9 activity in vivo after the cells 
was treated with siRNA and challenged with cisplatin. The fluorescent compound produced 
by activated caspase-9 was measured in the intact cells. Similar patterns of caspase-9 
inhibition by p53 were observed both in vivo (Figure 3.9A) and in vitro (Figure 3.9C), 
showing lowered caspase-9 activities and cleavage respectively.  
Both HEK293 and A2780 contain endogenous WTp53. It was therefore interesting to 
see if mutant p53 could likely inhibit caspases activation using cell lines containing 
endogenous mutant p53. For this purpose, a pair of ovarian cell lines PEO1 and PEO4 was 
used for comparison. PEO1 and 4 are isogenic cell lines derived from a patient with ovarian 
adenocarcinoma, whereby PEO1 is the original established cell line which is cisplatin-
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sensitive while PEO4 was established when the same patient developed resistance to cisplatin 
[229]. Sequencing the p53 gene of these cell lines revealed a mutation at the p53 gene at 
codon 342, with a change of amino acid from arginine to proline (Figure 3.10A). Codon 342 
lies within the TD.  
Both cells lines were treated with 25µM cisplatin for 24 hours after knockdown of 
p53 to initiate apoptosis. The same assay used for A2780 (Figure 3.9A) was applied here to 
measure the caspase-9 activities. For the PEO1 cells (Figure 3.10B), no significant change in 
caspase-9 activity was observed with p53 knockdown. However, for the PEO4 cells (Figure 
3.10D), caspase-9 activity was increased in the p53-knockdown cells, and the increase 
became more significantly with cisplatin treatment.  
 
3.2.5 Overexpression of p53 Inhibits Caspase Activation 
 
As results from the in vivo p53 knockdown experiments were consistent with the 
hypothesis, another set of experiment was carried to overexpress the various p53 proteins in 
vivo and to analyze if the increased in p53 in the cells could lead to inhibition of caspase 
activation. WT and mutant p53 were overexpressed in the lung carcinoma H1299 p53
-/-
 cells.  
The genes encoding the various p53 proteins chosen for this study were cloned into the 
pXJ40-HA-GFP plasmid. The plasmid contains a cytomegalovirus enhancer at its promoter 
site which enables high levels of expression of the gene cloned downstream. Therefore, the 
cells transfected with the plasmids were harvested for caspase cleavage analysis as early as 6-
hour post-transfection to minimize the effect of p53-transactivated pro-apoptotic genes 
brought about by the overexpression of p53. S100 cytosolic extracts were obtained from the 
cells after transfection followed by the initiation of caspase activation by the addition of 
cytochrome-c. Caspase-9 activities were then measured using a caspase-9 specific substrate, 
which when cleaved by active caspase-9, yields a quantifiable colorimetric product pNA.  
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From Figures 3.11, it is apparent that increasing amount of the various mutant p53 in 
the cell lysates resulted in lower caspase-9 activities compared to the controls. These 
observations correlated with the results in Figures 3.1 and 3.2, where increasing amount of 
p53 caused decreased in caspase-9 activities. Interestingly, a different trend was observed in 
cells overexpressing WT-p53 (Figure 3.11A). The overexpression of low concentration of 
WT-p53 caused the slight inhibition of caspase-9 cleavage, while at higher concentration; 
there was a reverse in phenomenon, whereby the caspase-9 activities returned to the level 
observed in the control.  
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Figure 3.1. Verification of Purity and Structure of Recombinant p53. Recombinant p53 were 
overexpressed in E.coli BL21 cells by transfecting pET32b plasmids containing the various p53 genes. The 
shaded arrows (         ) marked the various molecular weight markers. The black arrow (        ) marked the 
monomeric recombinant p53 at approximately 74kDa. A) the recombinant p53 were extracted from the 
inclusion bodies in E.coli using sonication and the purity of the p53 protein extracted were shown in coomassie-
stained SDS-PAGE gels. B) Far-UV circular dichoism data of recombinant WT and mutant p53
R337H
 (extracted 
from Figure 6 Phua[224]). Data for WTp53 is in red, p53R337H is in blue, unfolded proteins of both species are 
in green and light blue.  C) The structure of the recombinant p53 from (A) was tested using various 
concentrations of glutaldehyde to induce cross-linking between the p53 monomers and shown in Coomassie 
blue stained SDS-PAGE gel. The white arrow (       ) marked the tetrameric recombinant p53 at approximately 
296kDa. D) Three sets of experiments presented in (C) were done and the band intensities for the various 
monomeric recombinant p53 at different glutaraldehyde concentrations were analyed and the change in band 
intensity with reference to the control (0% glutaraldehyde) were calculated (n=3).  
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Figure 3.2. Addition of Recombinant p53 Inhibits Caspase Cleavage in HEK293 S100 
Cell Lysate. A) S100 lysates from HEK293 cells were obtained and incubated with the various recombinant 
proteins for 1 hour after addition of equal amount of dATP and cytochrome-c to initiate caspase cleavage. 
Profile of p53 (i), Caspase-9 (ii), Caspase-3 (iii), Caspase-6 (iv), Caspase-8 (v), PARP (vi), cytochrome-c (vii) 
and GAPDH (viii). Lane 1: lysate without cytochrome-c challenge; Lane 2: lysate with cytochrome-c challenge; 
Lane 3: lysate with cytochrome-c challenge and addition of 0.3µM HST-tag protein; Lanes 4-7: lysate with 
cytochrome-c challenge and addition of 0.1µM of the various recombinant p53; Lanes 8-11: lysate with 
cytochrome-c challenge and addition of 0.3µM of the various recombinant p53. B) Band intensities of the p46 
fragment of caspase-9 in were measured using ImageJ and calculated with reference to the control lysate to 
obtain the percentage change in band intensities. ** denotes the fold change in the band intensity of the fractions 
with 0.3µM recombinant p53 vs. 0.3µM HST-tag was significantly different (p<0.05, n=3).  
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Figure 3.3. Addition of Recombinant p53 Inhibits Caspase Cleavage in HCT-116 p53
-/-
 
S100 Cell Lysate. S100 lysates from HCT-116 p53-/- cells were obtained and incubated with the various 
recombinant proteins for 1 hour after addition of equal amount of dATP and cytochrome-c to initiate caspase 
cleavage. Profile of p53 (i), Caspase-9 (ii), Caspase-3 (iii), Caspase-6 (iv), Caspase-8 (v), PARP (vi), 
cytochrome-c (vii) and GAPDH (viii). Lane 1: lysate without cytochrome-c challenge; Lane 2: lysate with 
cytochrome-c challenge; Lane 3: lysate with cytochrome-c challenge and addition of 0.3µM HST-tag protein; 
Lanes 4-7: lysate with cytochrome-c challenge and addition of 0.1µM of the various recombinant p53; Lanes 8-
11: lysate with cytochrome-c challenge and addition of 0.3µM of the various recombinant p53. B) Band 
intensities of the p46 fragment of caspase-9 in were measured using ImageJ and calculated with reference to the 
control lysate to obtain the percentage change in band intensities. ** denotes the fold change in the band 
intensity of the fractions with 0.3µM recombinant p53 vs. 0.3µM HST-tag was significantly different (p<0.05, 
n=3). 
 
  
0%
20%
40%
60%
80%
100%
120%
Control Cyt-c His Tag 0.1uM 
WT
0.1uM 
D42Y
0.1uM 
R175H
0.1uM 
R337H
0.3uM 
WT
0.3uM 
D42Y
0.3uM 
R175H
0.3uM 
R337H
Fo
ld
 C
h
an
ge
 in
 B
an
d
 In
te
n
si
ty
 w
it
h
 R
e
fe
re
n
ce
 t
o
 
N
e
ga
ti
ve
 C
o
n
tr
o
l
Change in Caspase-9 p46 Band Intensity in the Presence of 
Recombinant p53
** 
** 
Chee Lai Yuen  
77 
 
A) 
HST Tag (µM) 
M
a
rk
er
 - - 0.3 - - - -  
Recombinant p53 
(0.3µM) 
- - - WT D42Y R175H R337H 
Cytochrome-c - + + + + + + 
  
i)  
 
ii)  
 
 iii)  
 
iv)  
 
v)  
 
vi)  
 
vii)  
 
 
  
HST-p53 
HST 
Procaspase-9 (46kDa) 
Cleaved caspase-9 
(37/35kDa) 
Cleaved caspase-3 
(17kDa) 
Procaspase-3 (35kDa) 
Cleaved PARP (85kDa) 
PARP (120kDa) 
Cytochrome-c 
(12kDa) 
GAPDH 
(37kDa) 
51kDa 
39kDa 
19kDa 
39kDa 
39kDa 
28kDa 
19kDa 
97kDa 
64kDa 
39kDa 
64kDa 
HST-p53 
Chee Lai Yuen  
78 
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Figure 3.4. Addition of Recombinant p53 Inhibits Caspase Cleavage in A2780 S100 Cell 
Lysate. A) S100 lysates from A2780 cells were obtained and incubated with the various recombinant proteins 
for 1 hour after addition of equal amount of dATP and cytochrome-c to initiate caspase cleavage. Profile of p53 
(i), HST-tagged proteins (ii), Caspase-9 (iii), Caspase-3 (iv), PARP (v), cytochrome-c (vi) and GAPDH (vii). 
Lane 1: lysate without cytochrome-c challenge; Lane 2: lysate with cytochrome-c challenge; Lane 3: lysate with 
cytochrome-c challenge and addition of 0.3µM HST-tag protein; Lanes 4-7: lysate with cytochrome-c challenge 
and addition of 0.3µM of the various recombinant p53. A light exposure of the p53 profile was used and 
endogenous p53 in A2780 is only visible when the blot is overexposed. B) Band intensities of the p46 fragment 
of caspase-9 in were measured using ImageJ and calculated with reference to the control lysate to obtain the 
percentage change in band intensities (n=2).  
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B)  
 
 
 
 
Figure 3.5. Only the Addition of Recombinant p53 Inhibits Caspase Cleavage in A2780 
S100 Cell Lysate. S100 lysates from A2780 cells were obtained and incubated with the various recombinant 
proteins for 1 hour after addition of equal amount of dATP and cytochrome-c to initiate caspase cleavage. 
Profile of p53 (i), HST-tagged proteins (ii), GST-tagged proteins (iii), Caspase-9 (iv), Caspase-3 (v), PARP (vi), 
cytochrome-c (vii) and GAPDH (viii). Lane 1: lysate without cytochrome-c challenge; Lane 2: lysate with 
cytochrome-c challenge; Lane 3: lysate with cytochrome-c challenge and addition of 0.3µM HST-tag protein; 
Lanes 4: lysate with cytochrome-c challenge and 0.3µM of GST-tag protein; Lane 5: lysate with cytochrome-c 
challenge and 0.3µM of recombinant nuclephosmin protein; Lane 6: lysate with cytochrome-c challenge and 
0.3µM GST-WTp53 protein from commercial source; Lanes 7: lysate with cytochrome-c challenge and addition 
of 0.3µM of HST-tagged p53. A light exposure of the p53 profile was used and endogenous p53 in A2780 is 
only visible when the blot is overexposed. B) Band intensities of the p46 fragment of caspase-9 in were 
measured using ImageJ and calculated with reference to the control lysate to obtain the percentage change in 
band intensities (n=2). 
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Figure 3.6. Immunodepletion of Endogenous p53 in HEK293 S100 Lysate Accelerates 
Caspase Cleavage. Profile of p53 (A), Caspase-9 (B), Caspase-3 (C), PARP (D), cytochrome-c (E) and 
GAPDH (F). Cleavage Pattern upon addition of cytochrome-c to p53 immunodepleted HEK293T cell lysates. 
Lane 1: HEK293T S100 cytosolic lysate; Lane 2: HEK293T lysate immunodepleted with p53 antibody and 
challenged with cytochrome-c for 15min; Lane 3: lysate immunodepleted with p53 antibody and challenged 
with cytochrome-c for 1 hour; Lane 4: lysate immunodepleted with haemaglutinin (HA) antibody and 
challenged with cytochrome-c for 15min; Lane 5: lysate immunodepleted with HA antibody and challenged 
with cytochrome-c for 1 hour. 
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Figure 3.7. Immunodepletion of Endogenous p53 in A2780 cells Accelerates Caspase 
Cleavage. Profile of p53 (A), Caspase-9 (B), Caspase-3 (C), PARP (D), cytochrome-c (E) and GAPDH (F). 
Cleavage Pattern upon addition of cytochrome-c to p53 immunodepleted A2780 cell lysates. Lane 1: A2780 
S100 cytosolic lysate; Lane 2: A2780 lysate immunodepleted with HA antibody and challenged with 
cytochrome-c for 15min; Lane 3: lysate immunodepleted with p53 antibody and challenged with cytochrome-c 
for 15min; Lane 4: lysate immunodepleted with HA antibody and challenged with cytochrome-c for 1 hour; 
Lane 5: lysate immunodepleted with p53 antibody and challenged with cytochrome-c for 1 hour. 
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Figure 3.8. Knockdown of Endogenous p53 in HEK293 cells Accelerates Caspase 
Cleavage. Profile of p53 (A), Caspase-9 (B), Caspase-3 (C), PARP (D), cytochrome-c (E) and GAPDH (F). 
Cleavage Pattern upon addition of cytochrome-c to HEK293 S100 cytosolic lysates which were subjected to 
knockdown of p53 over 48-hour period. NC represents negative control which contained siRNA with scrambled 
p53 sequences. Lane 1: lysate of HEK293 cells transfected with NC siRNA with no cytochrome-c challenge; 
Lane 2: lysate of HEK293 cells transfected with siRNA against p53 with no cytochrome-c challenge; Lane 3: 
lysate of HEK293 cells transfected with NC siRNA with cytochrome-c challenge for 15 minutes; Lane 4: lysate 
of HEK293 cells transfected with siRNA against p53 with cytochrome-c challenge for 15 minutes; Lane 5: 
lysate of HEK293 cells transfected with NC siRNA with cytochrome-c challenge for 1 hour; Lane 6: lysate of 
HEK293 cells transfected with siRNA against p53 with cytochrome-c challenge for 1 hour. 
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Figure 3.9. Knockdown of Endogenous p53 in A2780 cells Accelerates Caspase 
Activities. A) A2780 cells were subjected to knockdown of p53 for 24 hours and subsequent challenge with 
25µM cisplatin for a further 24 hours. Endogenous caspase-9 activities of both cells lines were then measured 
using fluorescent substrate specific to caspase-9. ** denotes that the levels of caspase-9 activity between the 
siLamin and sip53 after cisplatin challenge are significantly different (p<0.05). B) Profile of p53 in A2780 total 
cell lysates. Lane 1: cells transfected with siRNA against Lamin A/C and challenged with PBS (control); Lane 
2: cells transfected with siRNA against Lamin A/C and challenged with 25µM cisplatin; Lane 3: total cell lysate 
of H1299 p53
-/-
 cells; Lane 4: cells transfected with siRNA against p53 and challenged with PBS; Lane 5: cells 
transfected with siRNA against p53 and challenged with 25µM cisplatin. C) Profile of p53 (i), Caspase-9 (ii), 
Caspase-3 (iii), PARP (iv), cytochrome-c (v) and GAPDH (vi). Cleavage Pattern upon addition of cytochrome-c 
to A2780 S100 cytosolic lysates which were subjected to knockdown of p53 for 24 hours. NC represents 
negative control which contained siRNA with scrambled p53 sequences. Lane 1: lysate of A2780 cells 
transfected with NC siRNA with no cytochrome-c challenge; Lane 2: lysate of A2780 cells transfected with 
siRNA against p53 with no cytochrome-c challenge; Lane 3: lysate of A2780 cells transfected with NC siRNA 
with cytochrome-c challenge for 15 minutes; Lane 4: lysate of A2780 cells transfected with siRNA against p53 
with cytochrome-c challenge for 15 minutes; Lane 5: lysate of A2780 cells transfected with NC siRNA with 
cytochrome-c challenge for 1 hour; Lane 6: lysate of A2780 cells transfected with siRNA against p53 with 
cytochrome-c challenge for 1 hour. 
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Figure 3.10. Knockdown of Endogenous p53 in PEO4 cells Accelerates Caspase 
Activities. A) Sequencing data of PEO1 and PEO4 DNA to show the mutation site at codon 342 of the p53 
gene. B & D) Both cells lines were subjected to knockdown of p53 for 24 hours and subsequent challenge with 
25µM cisplatin for a further 24 hours. Endogenous caspase-9 activities of both cells lines were then measured 
using fluorescent substrate specific to caspase-9. ** denotes that the levels of caspase-9 activity between the 
siLamin and sip53 after cisplatin challenge are significantly different (p<0.001). C & E) Profile of p53 of PEO1 
(C) and PEO4 (E) total cell lysates. Lane 1: PEO1/4 cells transfected with siRNA against Lamin A/C and 
challenged with PBS (control); Lane 2: PEO1/4 cells transfected with siRNA against Lamin A/C and challenged 
with 25µM cisplatin; Lane 3: total cell lysate of H1299 p53
-/-
 cells; Lane 4: PEO1/4 cells transfected with 
siRNA against p53 and challenged with PBS; Lane 5: PEO1/4 cells transfected with siRNA against p53 and 
challenged with 25µM cisplatin. F) Figure showing profile of the various caspases upon overexpression of 
p53
R342P
 in H1299 cells (extracted from Figure 10 of Phua[224]). 
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D) 
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Figure 3.11. Overexpression of p53 in H1299 p53
-/-
 Cells Inhibits Caspase-9 Activities. 
Profile of caspase-9 activities over a time course of 12 hours in S100 cytosolic lysates of H1299 p53
-/-
  cells 
overexpressing various amounts of pXJ40-HA-GFP-WTp53 (A), pXJ40-HA-GFP-p53
D42Y
 (B), pXJ40-HA-
GFP-p53
R175H
 (C) and pXJ40-HA-GFP-p53
R337H
 (D); A-D(i) shows the kinetics of caspase-9 activity over a time 
course of 12-hours; A-D(ii) shows the end-point caspase-9 activities. ** denotes that the levels of caspase-9 
activity between the overexpression of pXJ40-HA-GFP control and pXJ40-HA-GFP-p53 is significantly 
different (p<0.05); E) Western blot showing p53 expression (i) and GAPDH as the loading control (ii) in the 
same lysates used in (A) to (D). 
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3.3 Discussion 
 
The results obtained in this study strongly indicate that p53 inhibits the cleavage of 
caspases. This was observed where removal of p53 accelerated caspase cleavage and activity, 
but the presence of p53 inhibited caspase cleavage. These results were initially surprising as 
it is a common knowledge that p53 (as reviewed in Introduction) should induce apoptosis. 
However, further in depth literature review reveals evidence suggesting that this novel 
function of p53 might indeed be true. 
 As mentioned earlier, Guillou [220], Jiang [219] and Ghavam-Nasiri [250] have 
observed a correlation between high levels of cytoplasmic mutant p53 and greater radio- and 
chemo-resistance of tumour cells. In accordance with this, ovarian cancer tumours are also 
found to exhibit overexpression of WTp53 [251]. In addition, there are many papers reporting 
the presence of p53 with missense mutations in tumour cells. These reports altogether seem 
to indicate that there are additional functions of p53 that are yet unknown. In this study, it 
appears that an unknown function is the inhibition of caspase activation by p53. 
 Since multiple cellular stress signalling pathways converge upon p53, it is logical and 
desirable that the master regulatory switch be able to initiate or inhibit apoptotic signalling. 
The additional control afforded by p53, through its inhibition of the important apical death 
signalling component caspase-9, will also help safe-guard against “accidental” death 
signalling e.g. caused by heightened amount of PUMA, BAX and Bak (which are all 
upstream of caspase signalling) as a result of mild cytotoxic provocation.  
Given p53‟s importance in regulating cell fate, it is intriguing as to why this facet of 
p53 remained undiscovered until now. As reviewed in Chapter 1, the focus of research on 
p53 in oncology thus far has been on its inability to transactivate pro-apoptotic target genes 
such as p21 and Bax. As caspases remained unknown as transcriptional target genes of p53 
until very recently, p53‟s effect and direct interaction with caspases might have been 
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overlooked completely. Most importantly, for the current investigation, the use of a cell-free 
system derived primarily from cytosol and devoid of nuclear content, has allowed a focus on 
the transcription-independent influence of p53 in the caspase activation cascade. Also, the 
lack of mitochondria in the cell-free system, as well as the manual addition of cytochrome-c 
to the lysates limited the influence of p53 on Bax/Bak-mediated cytochrome-c release from 
the mitochondria, events which are upstream of caspase activation in an in vivo situation. All 
in all, the use of the cell-free system had been very crucial in uncovering the hitherto 
unknown oncogenic facet of p53 that is unrelated to its well-studied transactivation function.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12. Diagram showing the relationship between caspases in the caspase shunt pathway. Inhibition 
of caspase-9 by p53 will arrest the progression of the normal as well as the caspase shunt pathway, thereby 
suppressing apoptosis in cells.  
 
Caspase-9 is the most apical caspase activated in the mitochondrial apoptotic 
signalling pathway. When activated, downstream targets such as caspase-3 are also activated, 
which subsequently cleave and inactivate house-keeping genes like PARP to enable apoptosis 
to take place. In addition, a small amount of the caspase is usually shunted into the caspase 
Caspase-9 
Caspase-3 
Caspase-8 
Caspase-6 
Cyt-c Apaf-1 
Apoptosis 
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amplification loop for rapid signal amplification. It was previously demonstrated that 
caspase-9 activates caspase-3, which will in turn activate caspase-6 [244]. Caspase-6 then 
cleaves procaspase-8 [243], and activated caspase-8 back cleaves procaspase-3 [245], thereby 
completing the signal amplification loop (Figure 3.12). The caspase amplification loop is thus 
made up of various caspases cleaving one another in that sequential order, leading to an 
escalation of caspase activities enabling a swift death response. As such, inhibition of the 
apical caspase-9 by p53 not only serves to retard the mitochondrial death signalling pathway, 
but also effectively inhibits initiation and “snow-balling” of various caspase activations 
through the amplification loop. This will probably help protect against aberrant escalation of 
death signalling under very mild, non-threatening stress conditions.  
 The addition of the various recombinant p53 forms into HEK293, HCT-116 p53
-/-
 and 
A2780 cell lysates demonstrated the inhibition of caspases activation and cleavage by p53, 
from the most upstream initiator caspase-9, to the downstream proteins such as caspase-3 and 
PARP (Figures 3.2 to 3.5). Since the inhibition was already evident starting from caspase-9, it 
was assumed that caspase-9 is the target of p53 inhibition in the caspase cascade. This 
assumption was supported by the fact that in this cell-free system, factors influencing caspase 
activation that are upstream of cytochrome-c induced apoptosome formation were absent. 
Also, if p53 had targeted other more downstream caspases such as caspase-6 and caspase-8, 
inhibition of cleavage of the most upstream caspase-9 would not have been so pronounced.  
In addition, this set of experiments showed that the inhibition of caspase-9 was specific to the 
addition of recombinant p53, regardless of the tag (GST or HST) and source (commercially 
available vs. those produced in the laboratory).  
Using the same cell-free cytosolic system, the removal of endogenous p53 from both 
WTp53-expressing HEK293 and A2780 cells showed a reversed effect i.e. the acceleration of 
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caspase cleavage (Figures 3.6 and 3.7). This interesting observation could be the first 
evidence to show that endogenous WTp53 intrinsically inhibits caspase-9.  
To further investigate if this phenomenon exists in vivo, p53 was removed from 
HEK293 and A2780 cells by using siRNA against p53. Various forms of p53 were also 
introduced into p53-null cells by overexpression. In line with the results obtained from the 
immunodepletion experiments, knockdown of p53 in HEK293 and A2780 cells showed 
accelerated caspase cleavage and activity (Figures 3.8 and 3.9). While the immunodepletion 
experiments eliminate potential p53-mediated transcriptional effects, the in vivo knockdown 
experiments took into account these transcriptional activities within the cellular milieu. The 
fact that p53‟s inhibitory effect on caspase-9 was recapitulated in the in vivo setting as well 
served to strengthen the hypothesis of this study.  
p53‟s novel caspase inhibitory effect was further studied using ovarian cancer cell 
lines PEO1 and PEO4. The ability of p53 to inhibit caspase-9 was reproduced in the 
knockdown experiments in PEO4 cells (Figure 3.10D). Notably, the increase in caspase-9 
activity due to p53-knockdown was only seen in cisplatin-resistant PEO4 cells and not in 
cisplatin-sensitive counterpart, PEO1. Although both cell lines harboured the R342P 
mutation, the different effects on caspases could be due to differential cytotoxin-induced p53 
response in the two cell lines. Upregulation of p53 protein expression with cisplatin treatment 
appeared to be more pronounced in PEO4 than in PEO1 cells. This could thus explain the 
more obvious inhibitory effect exerted by p53 on caspase-9. The observation that 
overexpression of this mutation in H1299 p53
-/-
 cells was able to inhibit caspase activation 
(Figure 3.10F) also helped to substantiate this interpretation. A more probable explanation is 
that the concentration of cisplatin used to induce apoptosis in PEO1 cells was at 25µM, 
which is five times the concentration of the IC50 for this cell line. Hence, most of the PEO1 
cells would have been killed by the high dose of cisplatin. Thus, the caspase-9 activities 
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recorded would not an accurate reflection for this set of experiment. Taking all these into 
account, it is still very tempting to hypothesize that the mechanism of PEO4‟s cisplatin-
resistance is due to p53‟s inhibitory action of caspases. 
In the current investigation, both mutant and WT p53 were overexpressed in H1299 
p53
-/-
 cells in an attempt to substantiate the results obtained earlier on i.e. the addition of 
recombinant p53 into cell-free lysates. Expectedly, increased overexpression of the various 
mutants led to decreased caspase-9 activities measured using colorimetric assays (Figure 
3.11). Although p53
R175H
 was previously shown to be able to downregulate the expression of 
procaspase-3 [233], the activity of the more upstream caspase-9 was measured instead, and 
the trend registered was presumed not to be markedly affected by changes in the protein level 
of the downstream caspase-3.  
It is of great interest to note that while the mutant p53 demonstrated a concentration-
dependent inhibition of caspase-9 activities in vivo, WTp53 was only able to inhibit caspase-9 
when overexpressed at very low amounts, although not at a level which is statistically 
significant (p=5.9%). At higher levels of WTp53 overexpression, caspase-9 activities 
increased to the control level. Bearing in mind that in the face of acute cytotoxic or genotoxic 
stress, dramatically heightened level of WTp53 can transactivate pro-apoptotic genes like Bax 
and Bak, expression of p53 at low level in this study might not be sufficient to tip the cell fate 
balance towards apoptosis. In this scenario, the slightly heightened amount of p53 may serve 
to instead inhibit nascent cell death signalling and perhaps allow for cell repair to occur. 
Conversely, with very high level of p53 overexpression, transactivation of the pro-apoptotic 
genes would have been rampant, and thus shifted the cell fate balance towards apoptosis. 
While the large amount of p53 could still inhibit active caspase-9, the p53-mediated 
expression of the array of pro-apoptotic genes such as Bax and Bak could have brought about 
massive cytochrome-c release from the mitochondria, wide-spread apoptosome formation and 
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consequently, run-away unbridled caspase-9 activation that became impossible to be 
quenched by the p53 expressed by the cells. However, it will be interesting to see if 
overexpression of an even lower concentration of WTp53 can result in a significant reduction 
in caspase-9 activity. 
One thing to note in this set of experiments was that a much higher level of the mutant 
p53 had to be expressed for the inhibition of caspase-9 to be significant (Figure 3.11E).  This 
is in contradiction to the earlier results where equal amount of recombinant p53 (WT or 
mutant) were able to inhibit caspase-9 activation. A possible explanation for this 
phenomenon is that in this in vivo experimental setup, the expressed p53 proteins may have 
undergone post-translational modification(s), which is most likely absent in the earlier 
experiments. Mutant forms of p53 have previously been reported to be hyperphosphorylated 
and acetylated as compared to its WT counterparts [184,185,252].  Among the sites which are 
phosphorylated in mutant p53, Ser392 was found to phosphorylated in high frequency in 
transitional cell carcinoma [185] and its phosphorylation correlated with lower patient 
survival in esophageal squamous cell carcinoma [187,188]. Phosphoryation of Ser392 was 
found to stablize p53 tetramers and increase its ability to bind DNA [253,254]. A possible 
mechanism which could have increase the demand for the mutant p53 protein in this 
experiment is that the mutant p53 proteins were sequestered at the various DNA binding sites 
due to its higher affinity for DNA in these Ser392-phosphorylated mutants. This leaves a 
lower level of free mutant p53 proteins which could then exert its inhibitory effects on 
caspase-9 and hence its activity.  
In summary, the results have suggested a possible role of p53 in the inhibition of 
apoptosis, possibly through the inhibition of caspase-9. This was not only shown through the 
use of different in vitro and in vivo techniques, but also demonstrated in a variety of cell 
lines. Cell lines established from either viral-induced transformation - HEK293 and 
Chee Lai Yuen  
100 
 
HEK293T; or derived from tumours – HCT116 p53-/-, H1299 p53-/- and A2780, were able to 
show similar phenomenon i.e. the inhibition of caspase activation when p53 is present. 
Although it can be argued that the p53 protein in HEK293 and HEK293T proteins are 
inactivated by E1B 55k [226,227] and SV40 large T-antigen [228] respectively, the fact that 
both immunodepletion and knock-down of p53 in the HEK cell lines as well as those derived 
from tumours (A2780 and PEO4) showed the same results suggested that the inhibitory 
function of p53 on caspases is independent of its interaction with the viral proteins. 
Moreover, the inhibition of p53 by both viral proteins (i.e. E1B 55k and SV40 large T-
antigen) are targeted at its transactivation activities [227,255,256]. However, the technique 
used to initiate caspase activation in the above experiments was through the use of 
recombinant cytochrome-c in S100 lysates, which is transcription-independent. It can also be 
argued that the inhibition of caspases seen in the results obtained is due to E1B 19k which 
interacts and inhibits Bax-dependent apoptosis [257]. Again, the use of the S100 fractions 
and cytochrome-c inititated caspase activation is independent of the mitochondria and Bax-
dependent perturbation of the mitochondria membrane. Hence, the participation of the viral 
proteins used in the immortalization of the HEK293 and HEK293T cells is minimal.  
 
3.4 Concluding Remarks 
 
The results obtained so far have been unexpected and could possibly open up a whole 
new dimension for p53 research in the study of oncology. The ability of p53 to induce 
apoptosis through transactivation and direct interaction with apoptotic proteins has been a 
major focal point for the past 30 years. Such dominant effects of p53 on apoptosis could have 
masked the hidden function of p53 in caspase inhibition, revealing itself only in the 
background of mutant p53 cells that are incapable of inducing transactivation-dependent 
apoptosis. Intriguingly, a study by Cao [40] showed that the abrogation of the transactivation 
activities of p53 was not sufficient to bring about transformation in epithelial cells. Apoptotic 
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resistance and aggressiveness in tumours harbouring such mutants appear to suggest that p53 
does indeed possess some death-signalling related function that remained unknown until now.  
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Chapter 4 – Results 
 
Direct Interaction between p53 and Caspase-9 
 
4.1 Introduction 
 
 Protein-protein interactions form the basis of most cellular signalling processes. Such 
associations often lead to structural changes which inhibit or activate the target proteins. 
Some proteins even become permanently attached to their target to alter the latter‟s functions. 
A known interacting partner of p53 is MDM2, which binds to p53 directly for inhibition. 
More examples of negative regulators of p53 have been reviewed in Chapter 1, Section 1.3.  
p53 itself can also act as an inhibitor in other cellular processes. For example, Sommers [258] 
demonstrated that p53 regulated the WRN helicase activities through direct interaction 
between the two proteins. p53 can also function as an activator of the pro-apoptotic protein 
Bak through direct interaction as well [97].  
In comparison to the deluge of reports focusing on the transactivation functions of 
p53, there are fewer reports on p53 as a modulator of cellular activities through direct 
interaction with the target proteins. This could be partly because such direct interactions are 
hard to detect. The discovery of p53‟s inhibitory effect on caspase-9 in this study could 
therefore be an addition to the few studies which report the transcription-independent roles of 
p53. 
 
4.2 Results 
 
4.2.1 p53 Inhibits the Activity of Caspase-9 Directly 
 
 To investigate if the inhibition of caspase-9 by p53 was direct, an assay monitoring 
the activity of active recombinant caspase-9 was used. Using a highly-purified recombinant 
system consisting of only recombinant p53 and active caspase-9, the direct effect that p53 
exerts on the activity of caspase-9 was measured without interference of other proteins as 
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found in cell lysates or other in vivo systems. Hence, any significant changes in the activity of 
caspase-9 could be attributed purely to the action of the added recombinant p53. Figure 4.1 
shows an at least 50% decrease in the activities of caspase-9 with addition of any of the four 
recombinant p53 (WT or mutants). The results showed that recombinant p53 is able to 
directly inhibit the activities of cleaved caspase-9. 
 Recombinant p53 was also added to caspase-3 and caspase-6 to investigate the 
former‟s effect on caspases other than caspase-9. From Figure 4.2, it can be seen that the 
recombinant p53 was unable to cause any significant reduction in the activities of both 
caspase-3 and caspase-6. It thus appears that p53 specifically inhibits caspase-9 and not other 
caspases.  
 In order to further affirm the specificity of the various recombinant p53, increasing 
concentrations of the recombinant p53 were titrated to determine if caspase-9 activities were 
correspondingly decreased. Indeed, all the recombinant p53 proteins tested were able to show 
an inverse correlation between the concentration of the p53 protein used and the caspase-9 
activity, even though the difference were the least obvious in p53
R337H
 (Figure 4.3).  
 
4.2.2 Inhibition of Caspase-9 Activities Requires a Folded Recombinant p53 
 
 So far, the inhibition of caspase-9 activities in this Chapter was demonstrated using 
recombinant p53 proteins that were folded. The next question to ask was whether the 
inhibition of caspase-9 is dependent on the recombinant p53 acquiring the correctly folded 
structure, or on a specific amino sequence within the p53 protein. To answer this question, a 
comparison of the effects of the unfolded p53 (in denaturing 6M urea) and those that were 
refolded (dialysed with refolding buffer) on caspase-9 activities was performed. Both types of 
p53 were added to the S100 cytosolic lysates of HCT116 p53
-/-
 cells to probe for the effects 
on the caspase cleavage patterns. To compensate for any effects which could have been 
caused by the 6M urea, an equivalent amount of 6M urea were added into the lysates where 
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folded recombinant p53 proteins were tested. Conversely, the equivalent amount of dialysis 
buffer was added into lysates where unfolded recombinant p53 proteins were used. In Figure 
4.4, it was clear that only folded recombinant p53 was able to inhibit the cleavage of caspase-
9 and the subsequent proteins in the pathway. Conversely, unfolded p53 were unable to show 
any inhibitory effects on active caspase-9. The results here indicate a structural requirement 
for p53‟s inhibitory activity on active caspase-9.  
 
4.2.3 p53 Interacts with Active Caspase-9 in vivo 
 
 Since all the in vitro experiments were able to demonstrate clearly that p53 directly 
inhibits the active form of caspase-9, immunoprecipitation (IP) was performed to analyse if 
p53 interacts with caspase-9 in vivo. Cleavage of caspase-9 was initiated in S100 cytosolic 
extracts of HEK293 cells using cytochrome-c, and subsequently an antibody specific to p53 
were used to immunoprecipate endogenous p53 from the lysates. From Figure 4.5, a band 
corresponding to the p35 band of caspase-9 co-precipitated with the endogenous p53. 
However, the result from this immunoprecipitation experiment was not always reproducible 
and thus a method for probing transient protein-protein interaction was utilised, as presented 
below.   
  
4.2.4 Interaction between p53 and Caspase-9 is Transient 
 
Despite numerous attempts to optimise the co-immunoprecipitation experiments, they 
were not successful in pulling down both caspase-9 and p53 together. Suspecting that the 
interaction between the two proteins is transient, attempts were made instead to detect 
transient protein-protein interaction using a cross-linking protocol reported by Melcher [259]. 
Based on this report, cross-linking between interacting proteins was induced with the addition 
of nickel acetate and MMPP. In this method, MMPP oxidizes the Ni(II) in the His-tag to 
highly electrophilic Ni(III), which in turn extracts an electron from a nearby aromatic side 
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chain, particularly a tyrosine. Finally, a covalent bond is formed between the His-tag and the 
tyrosine residues of the interacting proteins that are in close proximity. The nickel acetate 
helps to saturate the environment with free Ni
2+
 ions to aid the cross-linking reactions. All 
three components i.e. proteins, metal ions (Ni
2+
) and oxidants (MMPP) must be present in 
order for cross-linking to take place [260]. HST-tagged recombinant p53 used in this study 
were added into the cytochrome-c challenged S100 lysates of HEK293 cells to allow for their 
interaction with the endogenous active caspase-9. Nickel beads specific for His-tagged 
proteins were added to the lysates to extract the HST-tag (control) and the HST-tagged p53 
proteins. As the interaction was so transient, only one wash of the beads were performed 
before the cross-linking to avoid washing away the caspase-9 bound to the recombinant p53. 
Then, the three components used in Melcher‟s protocol were added to induce the formation 
of covalent bonds between the His-tag and the tyrosine residing in, presumably caspase-9. 
The beads were then washed extensively and analysed for the presence of p53 and caspase-9. 
Although lysates with HST-tagged p53 added showed higher pull-down of the p35 fragment 
of caspase-9, the control fraction were contaminated with small amount of both p53 and 
caspase-9 (Figure 4.6), which could arise from the initial not-so-stringent wash of the beads 
before the cross-linking reagents were introduced. 
To further verify this result, experiments using the “far Western” technique were 
performed. The experimental protocol was based initially on the report by Srinivasula [239] 
which demonstrated the interaction between caspase-9 and XIAP using far Western, and 
subsequently the one published by Wu [231]. Initially, no positive result was observed. As 
results from the IP experiments provided strong evidences that the transient interaction 
between the two proteins could not be detected under normal circumstances, modifications 
were again made to include a cross-linking step into the far Western protocol. A detailed 
protocol of this set of experiments can be found in Section 2.17.  
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Nitrocellulose blots containing renatured proteins were exposed to equal amounts of 
either recombinant HST-tag or HST-tagged-p53, subjected to cross-linking reactions, and 
subsequently exposed to either anti-S-tag or anti-p53 antibodies to detect the bound HST-
tagged p53. To visualise the profile of the caspase-9 proteins used for this experiment, a 
Western blot using antibodies against caspase-9 was performed. From Figure 4.7B, it can be 
seen that in Lane 1, both the p46 procaspase-9 and the p35 active caspase-9 bands were 
present at approximately equal amounts. In Lane 3, a thick band corresponding to the p35 
fragment was present while small traces of the p12 band were also there. In Lane 4, the p46 
procaspase-9 band and small traces of the p35 band were present. The HST-tag was loaded in 
Lane 2 to act as a control, and the bands showed up when the blots were exposed to anti-S-
tag antibodies (Figure 4.7A, E & F).  
Analyzing the profiles in greater detail, it can be seen that in Lane 1, multiple bands 
were observed when blots were exposed to recombinant p53 (Figure 4.7C & E) and not the 
HST-tag (Figure 4.7D & F). As Lane 1 contained proteins from the S100 cytosolic fraction 
from H1299 p53
-/-
 cells, the multiple bands observed in Lane 1 were most probably 
contributed by the interaction of the recombinant p53 with the cytoplasmic components e.g. 
Bak. Moving on, there were no bands observed in Lane 2 when blots were exposed to 
recombinant p53 (Figure 4.7C & E). This hence showed that there were no unspecific 
interaction between the recombinant p53 or the HST-tag attached to the recombinant p53 and 
the HST-tag present on the blots. The presence of the HST-tag on the blots were clearly 
demonstrated when the blots were exposed to anti-S-tag antibodies (Figure 4.7D & F). In 
Lane 3, a band corresponding to the p35 fragment of caspase-9 was present in both blots 
exposed to recombinant p53 (Figure 4.7C & E) but not in blots exposed to HST-tag (Figure 
4.7D & F). This hence further iterates that only the recombinant p53 was interacting with the 
caspase-9 and the reaction was not due to unspecific interactions with the HST-tag. Also, in 
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Figure 4.7D, there were no bands present except for one in Lane 1, which corresponded to the 
GFP-tagged-WTp53 expressed in the H1299 p53
-/-
 cells. This result hence acts as an antibody 
control to verify that the results obtained for C) and E) were not false positives due to 
unspecific binding of the antibody. Finally in Lane 4, several bands were evident in all blots 
except the one exposed to HST-tag and anti-p53 antibodies (Figure 4.7D). This again showed 
that the HST-tag on the p53 proteins did not interact unspecifically with the caspase-9 present 
in this lane. Also, it is an important piece of evidence to prove that p53 does not interact with 
the p46 procaspase-9 fragment. The bands that showed up in Lanes 4 on the other blots could 
have been contributed by interaction between p53 and the IVT components (which were not 
removed as both the expressed caspase-9 and the IVT components were His-tagged). 
In summary, blots that were exposed to recombinant WTp53 and anti-S-tag or anti-
p53 antibodies showed a unique band in Lane 3 which corresponded to the 35kDa active 
caspase-9 fragment (indicated by the red arrows). No bands at 46kDa and 12kDa for lanes 
containing caspase-9 were detected, suggesting that the interaction occurs between p53 and 
specifically p35 fragment of caspase-9. This is in agreement with the results obtained for the 
IP experiments. 
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A) 
 
  
B) 
 
 
Figure 4.1. Recombinant WT-p53 and the Various Mutants inhibit the Activity of 
Recombinant Active Caspase-9 Directly. Activity of caspase-9 was measured through the release of 
pNA from the cleavage action of active caspase-9 on the LEHD-pNA substrate. 1µM of recombinant p53 was 
used with 2.8 µM of active recombinant caspase-9 and 200 µM of LEHD-pNA substrate. The data obtained 
were expressed as A) over a time course of 60 munites at 2-minute intervals and B) the final measured caspase-9 
activities in the different conditions. ** denotes that the caspase-9 activity is significantly different from the 
positive control and the HST-tag (n=4, p<0.001).  
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C) 
 
  
D) 
 
  
Figure 4.2. Inhibition of Caspase Activities is Specific to Caspase-9. Activities of the various 
caspases were measured through the release of pNA from the cleavage action of the active of the respective 
caspases on their substrate coupled to pNA. 1µM of the various recombinant p53 were used with A & B) 20nM 
of active recombinant caspase-3 were used with 200µM of Ac-DEVD-pNA substrate; C & D) 25nM of active 
recombinant caspase-6 were used with 200µM of Ac-VEID-pNA were used. All reactions were measured over a 
time-course of 60 minutes at 2-minute interval.  
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Figure 4.3. Dosage-Dependent Inhibition of Recombinant Active Caspase-9 Activity by 
Recombinant WT-p53 and the Various Mutants. Activity of caspase-9 was measured through the 
release of pNA from the cleavage action of active caspase-9 on the LEHD-pNA substrate. Various concentration 
of recombinant p53: WT (A), D42Y (B), R175H (C) and R337H (D) were used with 2.8 µM of active 
recombinant caspase-9 and 200 µM of LEHD-pNA substrate. Activties were measured over a period of 60 
minutes at 2-minute interval. 
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Figure 4.4. Inhibition of Caspase-9 by p53 Require a Folded Protein Structure. S100 
lysates from HCT116 p53
-/-
 cells were obtained and incubated with the various recombinant proteins for 1 hour 
after addition of equal amount of dATP and cytochrome-c to initiate caspase cleavage. [UF] depicts unfolded 
recombinant proteins whereby p53 still in 6M urea were added to refolding buffer (Section 2.3) without dialysis. 
[F] depicts recombinant p53 which has gone through the refolding and dialysis process. Profile of p53 (A), 
Caspase-9 (B), Caspase-3 (C), PARP (D), cytochrome-c (E) and GAPDH (F). Lane 1: lysate without 
cytochrome-c challenge; Lane 2: lysate with cytochrome-c challenge; Lane 3: lysates with cytochrome-c 
challenge and addition of 0.13M of urea (this concentration was calculated based on the volume of 6M urea 
which would be present in the lysate after dilution with dialysis buffer); Lane 4: lysate with cytochrome-c 
challenge and addition of 0.3uM recombinant HST-tag protein; Lanes 5-12: lysate with cytochrome-c challenge 
and addition of 0.3µM of the various [UF] and [F] recombinant p53. 
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Figure 4.5. Immunoprecipitation of p53 in HEK293 Cells Shows Interaction of p53 and 
Active Caspase-9. S100 cell lysates were harvested from 293 cells. Lysates were challenged with 
cytochrome-c for 30 minutes before equal amounts of lysates were added to Dyna beads coupled with either 
anti-HA or anti-p53 antibodies.  Western blot was then performed probing for p53 and caspase-9. Unchallenged 
lysates (Lane 1) and cytochrome-c challenged lysate (Lane 2) were loaded as positive control. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6. Immunoprecipitation of p53 in HEK293 Cells with the Addition of His-
tagged Recombinant p53 showed more pull-down of Endogenous Active Caspase-9. S100 
cell lysates were harvested from 293 cells. Lysates were challenged with cytochrome-c for 30 minutes before 
0.1µM of His-tagged or His-tagged recombinant p53 were added to equal volumes of the cytochrome-c 
challenged lysate. Nickel beads specific for His-tagged proteins were used to extract the His-tagged proteins 
from both lysates. Western blot was then performed probing for p53 and caspase-9. Cytochrome-c challenged 
lysates (Lane 1) and unchallenged lysate (Lane 2) were loaded as positive control. 
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Figure 4.7. p53 Interacts with Active Caspase-9 via Far Western. The blots contained S100 
lysate of HCT116 p53
-/-
 overexpressing WTp53 (Lane 1); 0.5mg of HST-tag expressed from pET-32b plasmid 
(Lane 2); 15ng active caspase-9 (Lane 3); and 1µl of IVT mixture containing procaspase-9 (Lane 4). A) Protein 
profile shown using Coomassie staining. B) Caspase-9 profile detected using Western blot. C&D) Detection of 
interacting proteins using HRP-coupled-DO-1 p53 antibodies via far Western technique. E&F) Detection of 
interacting proteins using HRP-coupled-S-tag antibodies via far Western technique. The red arrows show the 
specific interaction between the recombinant WTp53 and the p35 fragment of caspase-9. 
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4.3 Discussion 
 
 So far, the results discussed in Chapter 3 revealed the phenomenon of caspase-9 
inhibition by p53. In this Chapter, the results garnered support the hypothesis that p53 
inhibits the action of caspase-9 through direct interaction. 
 Using pure recombinant systems, all four recombinant p53 were able to reduce the 
activity of active caspase-9 significantly (Figure 4.1). This inhibitory action was further 
shown to be specific to caspase-9 (Figure 4.2) and dependent on the concentration of the 
recombinant p53 proteins (Figure 4.3). The inhibitory effects of the four p53 forms were 
almost identical in this set of experiments except that p53
R337H
 was able to inhibit caspase-9 
activities more markedly at lower concentrations as compared to the other three p53 proteins. 
It could be that p53
R337H
 possess the highest affinity for the active caspase-9 molecules and 
that a small amount the mutant protein was able to bring about a higher level of inhibition of 
caspase-9 as compared to the other p53 proteins. Notably, increasing p53
R337H
 further to 
0.5µM and 1.0µM did not bring about further marked decrease in caspase-9 activity, 
indicating that a saturation of the inhibitory effect might have been attained. Also, the 
inhibition on caspase-9 was shown to be structurally dependent (Figure 4.4). Most 
interestingly, differences in the inhibition of caspase-9 were obvious between the unfolded 
and folded structural mutant p53
R175H
. This suggests that some protein structure might have 
been induced by the refolding procedure, and that this minimal structural conformation is 
sufficient in mediating the inhibition of caspase-9. 
The idea of an inhibitor that targets the active form of caspases is not unprecedented 
in the field of apoptosis study. Proteins with similar mode of action have already been 
discovered, such as members of the IAP (inhibitor-of-apoptosis) family. The mammalian IAP 
proteins were discovered due to their homology to the baculoviral apoptotic inhibitor [261]. 
All family members possess a RING finger domain in their C-terminus and at least one BIR 
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(Baculovirus IAP Repeats) domain in the N-terminus [262]. To date, the better known 
members of this family include X-linked IAP (XIAP) [263], Survivin [264] and more 
recently, Livin [265]. Studies have revealed some very powerful properties of these proteins 
in coordinating cellular responses to apoptosis.  
The IAP proteins have been demonstrated to regulate both initiator and effector 
caspases by binding to and inhibiting the actions of cleaved caspases such as caspase-9 and 
caspase-3 [265-267]. For example, XIAP was found to bind to monomeric caspase-9. As the 
activities of caspase-9 is amplified manifold when present as a heterodimer of the p35 and 
p12 subunits [239], the binding action of XIAP to monomeric caspase-9 retards the ability of 
caspase-9 to form the highly active heterodimer molecules [267]. Although there is no 
evidence so far in this study to determine the mode of inhibition of p53 on active caspase-9, it 
is plausible that p53 could act and inhibit caspase-9 in a fashion similar to XIAP.  
Even though the inhibitory effects of p53 on caspase-9 can be easily observed as 
reported in Chapter 3, the direct interaction between p53 and caspase-9 was extremely 
difficult to prove using merely co-immunoprecipitation experiment. Out of every ten attempts 
(not including the numerous optimisation efforts) to pull down p53 and caspase-9 from cell 
lysates to show their interaction, only one succeeded (Figure 4.5).  
Postulating that the interaction might only be possible at very low concentrations, 
modifications were performed to the IP protocol, e.g. overexpression of either WTp53 or 
caspase-9 in the cells to increase the concentration of both proteins. However, the results 
remained negative despite these efforts. This led to the next hypothesis that the interaction 
between p53 and caspase-9 might be transient. Going along this line of thought, attempts 
were made to crosslink the two proteins during the IP experiments. Results from Figure 4.6 
appeared to show a pull-down of the p35 fragment of caspase-9 by the HST-tagged WTp53 
in a background of lingering cytoplasmic proteins. As minimal washing steps were utilised in 
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the protocol after the nickel beads were extracted from the cytosolic lysates, small amounts of 
p53 and the p35 of caspase-9 were detected in both IP fractions (Figure 4.6). In addition, 
traces of p37 fragment of caspase-9 were also present in both fractions. However, as the 
intensity of this band was similar in both fractions, it thus could serve as an internal control to 
verify the greater pull-down of the p35 fragment of caspase-9 by p53. In spite of all the 
explanations, this could only be used as a supporting result and is not conclusive on its own 
to confirm the direct interaction between endogenous p53 and active caspase-9. 
While showing the direct interaction between proteins using IP is an important step in 
determining whether the two proteins in questions work together, there are proteins which 
could influence the functions of their downstream targets without adhering to them. One such 
study was published by Chipuk [20]. In this report, p53 was shown to directly activate Bax 
and induce mitochondria membrane permeabilization. However, there were no evidence to 
demonstrate the direct interaction between p53 and Bax using traditional IP experiments. 
Instead, in vitro systems involving the pure components of the proteins under study i.e. p53, 
Bax, purified liver mitochondria, GST-Bcl-xL were reconstituted in different experimental 
conditions to study the effects of p53 on Bax and mitochondria permeabilization. Although 
no direct interactions between p53 and Bax were shown, the study proved undoubtedly that 
p53 could activate Bax directly. Hence, p53 could also influence the functions of caspase-9 
that could not be detected under normal physiological conditions using IP.   
In most experiments, interaction of proteins can be detected at ng or nM 
concentrations. For example, the report by Chipuk [20] as mentioned above was 
demonstrated with nM of recombinant Bax and p53, Li [85], showed the formation of the 
apoptosome at ng of the components, and Maiguel [268] proved the interaction between 
NPM and p53 using ng of GST-p53 protein. However, it does not exclude the possibility that 
interacting partners may physically associate only at much higher concentrations. Gannon 
Chee Lai Yuen  
120 
 
and Lane [269] demonstrated that interactions between T-antigen from SV-40 virus, p53 and 
DNA polymerase can only occur at concentrations of the components at µg levels. In another 
study, c-myc was shown to bind to DNA only at very high concentration [270]. In both cases, 
the high concentration needed to demonstrate the physical interactions did not undermine the 
physiological importance of such associations. In the current investigation, the reconstitution 
of the recombinant p53 and active caspase-9 at µg levels were able to show convincing trends 
of the inhibitory effect of p53 on caspase-9. Using conventional IP, µg level of endogenous 
p53 is already difficult to pull down. In addition, the detection of co-precipitated caspase-9 
will already be difficult, should the p53-caspase-9 interaction occur only at high protein 
concentrations. As such, the task of detecting such interaction will be even trickier if the 
interaction is transient.  
To circumvent the problems encountered using conventional IP protocols and the 
possibility of transient interaction between the two proteins, a modified far Western protocol 
was used. Srinivasula [239] employed this method to detect the interaction between XIAP 
and the p12 fragment of the active caspase-9 protein. After several optimisation and changes 
of protocols, the interaction between WTp53 and the p35 fragment of caspase-9 was finally 
detected (Figure 4.7C & E).  
By adding the same cross-linking step into the far Western protocol, interaction 
between p53 (WT and mutant) and the p35 fragment of active caspase-9 was evident. One 
puzzling observation that emerged was that although the p35 caspase-9 fragment were in 
higher concentration to the ones generated using IVT (compare intensity of bands in Lane3 
and 4 in Figure 4.7B), a stronger signal from the p35 band in Lane 4 (as compared to the one 
in Lane 3) was observed (Figure 4.7C & E). Even though it seems to suggest that the 
recombinant p53 binds better to the p35 fragment produced by the IVT system, a more 
plausible explanation would be that the stronger signal was due to the interaction between 
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p53 and one of the IVT components that bore similar molecular weight to the p35 fragment 
of caspase-9. The presence of other bands on Lane 4 though, could be attributed to unspecific 
interactions between the HST-tag of the recombinant p53 or the HST-tag itself and the 
components of the IVT systems. 
In summary, the interaction between p53 and the p35 fragment of caspase-9 was 
demonstrated using recombinant systems i.e. activity assays and far Western, semi-
recombinant systems (IP with HST-tagged recombinant p53) and endogenous proteins 
(conventional IP). The data obtained from all these experiments demonstrated the existence 
of the elusive p53-caspase-9 interaction, and appears to further point to a transient nature of 
such interaction. 
 
4.4 Concluding Remarks 
 
The results obtained so far help to substantiate the claim that the inhibitory action of 
p53 occurs via its direct action on active caspase-9. Furthermore, results from IP and far 
Western experiments confirmed the interaction of p53 and the p35 active subunit of caspase-
9. This is in reminiscent to the interactions seen between caspase-9 and Survivin [271], Livin 
[265] and XIAP [239]. This interaction between p53 and caspase-9 appears to be transient 
and could only be detected when both proteins were present at very high concentrations. This 
could thus explain why the association between the two proteins had eluded detection by the 
scientific community for so long, even after the development of highly sensitive methods 
such as yeast-two-hybrid assay and Tandem affinity purification with mass spectrometry-
based proteomics, to detect interacting partners. 
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Chapter 5 – Results 
 
p53 Mediates Cell Survival Through Caspase-9 Inhibition 
 
5.1 Introduction 
 
 Many of the known caspases are involved in death signalling, and thus inhibiting the 
activities of these caspases will perceivably impact on cell survival and oncogenic 
transformation. Given the findings reported in this thesis of p53 as a novel inhibitor of active 
caspase-9, the next logical step is to investigate how such inhibition would impact cell 
viability and possibly underlie the oncogenic processes. 
 As mentioned in Chapter 1, the proportion of ovarian cancer tumours with p53 
mutations is the highest (approximately 50%), as compared to the other types of cancer 
tumours (Figure 1.5B). Indeed, in serous ovarian cancer, a recent report suggests that the 
mutation rate determined using clonal sequence may be over 96% [272]. Among the many 
studies attempting to correlate p53 mutation with p53 overexpression status and patient 
prognosis, the study by Rele [146] found that patient survival decreased when ovarian 
tumours had both p53 overexpression and mutation. Also, missense mutations in p53 were 
found in the same study to be more prevalent in advanced ovarian cancer stage. In another 
report, patients who responded unfavourably to platinum-based chemotherapy had a higher 
occurrence of p53 mutation [273]. Taken together, these studies suggest that p53 mutation 
and overexpression in these tumours may indeed contribute to their more aggressive nature.  
 cis-diamminedichloroplatinum(II), or cisplatin, is a very common drug used in 
treating ovarian cancer. It was approved for clinical use in both ovarian and testicular cancer 
since 1978 [274]. It is also widely administered in bladder, cervical, head and neck, small-cell 
and non-small cell lung cancers [275]. Cisplatin belongs to a class of platinum-based drugs, 
which when aqueous, forms positively charged molecules that crosslink to DNA. 
Consequently, DNA/platinum adducts result from these cross-linkages [276]. The most 
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common adduct is an intrastrand crosslink between adjacent guanines [277]. The DNA 
damage caused by adduct formation then elicits a p53-dependent apoptotic response [278], 
thus leading to the demise of the actively dividing cancerous cells.   
 Studies have revealed that ovarian cancers with p53 mutation showed higher 
resistance to cisplatin treatment [146,279], thus suggesting that p53 may play a crucial role in 
enhancing the survival of these tumour cells. With this in mind, the hypothesis here is that the 
presence of both WT and p53 missense mutants can enhance cell survival in the face of 
cisplatin treatment, through the inhibition of apical caspase-9 and consequently, cell death 
signalling. 
 
5.2 Results 
 
5.2.1 Apoptosis was Elicited in HCT116 p53
-/-
 cells when Challenged with Cisplatin 
 
To ensure that the mitochondria pathway is activated in HCT116 p53
-/-
 cells upon 
cisplatin administration, the cells were first exposed to different concentrations of cisplatin. 
From Figure 5.1B, the growing intensity of the cleaved PARP band with increasing cisplatin 
dosage used indicated that this apoptotic pathway was activated. However, at 1mM cisplatin, 
the procaspase-9 band was almost as intense as the one at 0.1mM dosage (Figure 5.1A), 
suggesting that this concentration of cisplatin was not efficient in activating the mitochondria 
pathway. Hence, a 0.5mM cisplatin concentration was selected to be used in the following 
experiments. 
 
5.2.2 p53 Overexpression offered Protection Against Cisplatin-induced Cell Death 
 
 After establishing the concentration of cisplatin to use, HCT-116 p53
-/-
 cells were 
transfected with pXJ40-HA-GFP plasmids containing the genes for WT or the various p53 
mutants, followed by treatment with 0.5mM of cisplatin over 72 hours. In Figure 5.2A, the 
control cell population showed no significant difference in cell survival over the time course. 
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However, all forms of p53 (except p53
R175H
) induced a greater extent of cell survival 
compared to the GFP control. The cytoprotection was most prominent at the end of the 72-
hour period, with p53
D42Y
 showing the highest percentage of cell survival, followed by 
WTp53 and lastly p53
R337H
.  For p53
R175H
, there were no significant differences in the extent 
of cell death when compared to the GFP control, indicating that overexpression of this mutant 
in HCT-116 p53
-/-
 cells might not confer marked cell death resistance against cisplatin.  
 
5.2.3 Cytoprotection of Cells Harbouring p53 was Mediated through Reducing Caspase-9 
Activity 
 
 After establishing that p53, WT or mutants alike, were able to afford protection 
against cell death in the presence of cisplatin, the next step was to determine if the enhanced 
resistance was due to the halted apoptotic signalling through the inhibition of caspase-9. 
HCT-116 p53
-/-
 cells were again transfected with the pXJ40-HA-GFP plasmids containing the 
genes for the various p53 types, followed by treatment with 0.5mM cisplatin. After a 72-hour 
exposure to the cytotoxin, the caspase-9 activities in the cells were imaged.  As can be 
seen from Figure 5.3A, cells overexpressing p53 had lower caspase-9 activity as compared to 
the GFP control. Also, there appears to be an inverse relationship between caspase-9 activity 
and the cytoprotection effect as shown in Figure 5.2A. Cells overexpressing WTp53 and 
p53
D42Y
 (which displayed the most cytoprotection in Figure 5.2A) had the lowest caspase-9 
activity. This is followed by cells overexpressing p53
R337H
. As expected, p53
R175H
 which 
showed no cytoprotective effect, did not exhibit any difference in caspase-9 activity when 
compared to the GFP control. Taken together, the results indicate the quenching of caspase-9 
by p53 may mediate cell death resistance afforded by the latter in the face of potent cytotoxin 
treatment.  
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Figure 5.1. Apoptosis was elicited in HCT-116 p53
-/-
 cells exposed to Cisplatin. HCT-116 
p53
-/-
 cells were exposed to increasing dosage of cisplatin for 72 hours and total cell lysate were obtained and 
probed for the profile of A) Caspase-9 and B) PARP protein.  
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B) 
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Figure 5.2. HCT-116 p53
-/-
 cells transfected with p53 Survived Better Under Cisplatin Drug Challenge. HCT-116 p53-/- cells were transfected with 
0.2µg of pXJ40-GFP-p53 for 4 hours before poisoning with 0.5mM of cisplatin. Cells were counted at every 24-hour period post-transfection. A) The percentages of 
transfected cells were calculated and the ratios of transfected cells in cisplatin to those in PBS were obtained. ** denotes that the cell survival at 72-hour of the cells 
overexpressing the various p53 is significantly different from the GFP control (n=3, p<0.05). B) shows the representative images used for the calculation of the ratios in (A).   
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Figure 5.3. HCT-116 p53
-/-
 cells transfected with p53 Survived Better Under Cisplatin Drug Challenge due to Inhibition of Caspase-9. 
HCT-116 p53
-/-
 cells were transfected with 0.2µg of pXJ40-GFP-p53 for 4 hours before poisoning with 0.5mM of cisplatin. Substrates that are specific to the action of active 
caspase-9 were added to the cells to yield a fluorescent product 1 hour prior to imaging. A) Cells positive for both GFP fluorescence and caspase-9 activity were counted and 
expressed as a ratio over the total number of GFP-fluorescence-positive cells. ** denotes that the caspase-9 activity of the cells overexpressing the various p53 were 
significantly different from the GFP control (n=3, p<0.01). B) shows the representative images used for the calculation of the ratios in (A).  
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5.3 Discussion 
 
 In line with the hypothesis stated at the beginning of this Chapter, the data 
demonstrated the enhanced survival of cisplatin-treated HCT-116 p53
-/-
 cells through 
p53-mediated quenching of caspase-9 activity. Such cytoprotective effects of p53 
(both WT and mutant) have already been reported in studies on ovarian cancer [146] 
and lung cancer [280]. With more reporting on the strong correlation between mutant 
p53 overexpression and enhanced cell survival, the long-standing hypothesis that the 
impairment of the transactivation property of mutant p53 is fully responsible for 
oncogenic transformation appears to be incomplete. This hypothesis cannot account 
for the phenomenon of tumours with overexpressed p53 showing enhanced invasion 
and metastasis in murine models [281,282].  In addition, the hypothesis also fails to 
explain the findings of tumours overexpressing WTp53 protein that has intact DNA 
binding ability, and hence the ability to induce apoptosis through transactivation of 
pro-apoptotic genes [161]. The findings that aggressive tumour cells usually exhibit 
both p53 mutation and overexpression are strong indications that the enhanced 
survival is not just dependent on the loss-of-function of WTp53, but also on a 
possible gain-of-function in mutant p53. The results here strongly indicate that the 
inhibition of caspase-9 activities by both WT and mutant p53 could contribute to the 
enhanced survival of tumour cells due to the impairment of cell death signalling. 
In this study, overexpression of WTp53 in HCT-116 p53
-/-
 cells resulted in 
greater extent of cell survival with cisplatin treatment, when compared to cells 
overexpressing p53
R175H
 and p53
R337H
 (Figure 5.2A). WTp53 possesses the ability to 
induce apoptosis through the transactivation and direct mitochondrial action. As 
such, the phenomenon observed here suggest that cells overexpressing the pro-
apoptotic WTp53 were even more robust than its counterparts overexpressing the 
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mutants in the face of cisplatin treatment, is both intriguing yet fascinating. In 
addition, caspase-9 activity in these cells was lower than those in the GFP control 
(Figure 5.3A), suggesting a decrease in apoptotic signalling. Correlating this 
observation with other reports showing WTp53 overexpression in brain [283], 
ovarian [251], breast [182] colorectal [178], and head and neck cancer [284], the 
caspase inhibitory role of WTp53 uncovered in this study can potentially explain 
these seemingly paradoxical findings. In addition, the data also suggest that the 
inhibitory effect on caspase-9 is an inherent function of WTp53, which is often 
masked by its pro-apoptotic functions.  
The p53 mutant that provided the most cell death-resistance to cisplatin is 
p53
D42Y
. By the end of the 72-hour treatment duration, there was on average a ten-
fold increase in cell survival as compared to the GFP control. As mentioned in 
Section 3.1, the choice of this mutation for this study is because of the location of the 
mutation (in the TAD region) and also because it is a mutation that was reported in 
ovarian cancer [236]. In addition, p53
D42Y
 is characterised by the more drastic amino 
acid substitution from a positive electrically charged side group (aspartic acid – D) to 
one with a hydrophobic side group (tyrosine – Y), as compared to the other mutants 
chosen (all involving arginine to histidine substitution – with both amino acids 
possessing side chains that are positively charged), and this would provide a good 
contrast in this current investigation. As shown in the results, the more severe change 
in the side chain properties in the D42Y mutant seemed to accentuate cisplatin-
induced cell death resistance and increase cell survival of cells overexpressing this 
mutant. The change in amino acid sequence and properties could have caused a 
structural change in the protein which retards p53‟s transactivation property, 
presumably by inhibiting the phosphorylation of serine 46. Phosphorylation at serine 
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46 was previously reported to be essential for the transactivation of the pro-apoptotic 
gene, p53AIP1 [285]. Thus, coupled to the inhibition of caspase-9 activity by the 
mutant, cells with p53
D42Y
 will be able to better resist the cytotoxic effects of 
cisplatin, as compared to the other p53 forms studied. Although the occurrence of 
this mutation in ovarian cancer is not very frequent [146,236], the potent effect of 
this mutant on cell death resistance and oncogenesis should not be dismissed. More 
work should be done to unravel the detailed mechanism underlying this mutant‟s 
influence on cell survival and drug resistance. 
Compared to WTp53 and p53
D42Y
, cells overexpressing p53
R337H
 also 
afforded resistance to cisplatin treatment, though not as potently as the former two in 
terms of its cytoprotective effect. The mutation at amino acid residue 337 lowers the 
ability of p53 to tetramerise, which is an essential step for the transactivation of p53 
target genes. Again, coupled to caspase-9 inhibition, the lack of transactivation by 
this mutant p53 could increase the threshold of cells to cytotoxin-induced apoptosis. 
Although the R337H mutation is not very commonly found in ovarian cancer, the 
tetramerisation mutants such as p53
K351N
 mutation occurs naturally in the cisplatin-
resistant ovarian cell line A2780-cis [44], while the p53
R342P
 mutant was found in the 
PEO cell lines derived from ovarian cancer patients [229]. Similar to the R337H 
mutation, both the K351N and R342P lie within the TD region, which could 
destabilize the p53 tetramer. The reduction of its transactivation abilities could then 
ensue, thereby preventing the p53-mediated expression of pro-apoptotic proteins 
such as Bax. Hence, the significance of mutations in the TD region should not be 
discounted. 
In contrast to the WT and the other two mutants, the structural mutant 
p53
R175H
 offered no protection against the cytotoxic effect of cisplatin. Also, there 
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was no significant difference in the caspase-9 activity of this population of cells and 
the control. This is in sharp contrast to the inhibitory effects displayed when the 
recombinant protein of this mutant was added to S100 lysates of HEK293 (Figure 
3.2) and HCT116 p53
-/-
 cells (Figure 3.3) and when it was overexpressed in H1299 
p53
-/-
 cells (Figure 3.11). The only difference between these two sets of experiments 
is that the induction of caspase-9 activation in the two former experiments were done 
in cell-free systems, while the overexpression and cisplatin challenge were 
completely in vivo. Thus while p53
R175H
 has the ability to inhibit caspase-9 in vitro, 
this structural mutant could no longer protect the cells from the effects of cisplatin in 
an in vivo setting. Cui [286] had reported previously that the neuroblast cell line SH-
SY5Y overexpressing this mutant form of p53 was able to inhibit caspase-9 cleavage 
after doxorubicin administration. Coupled with the fact that R175H mutation is a 
rather prevalent mutation in ovarian cancer, it is rather surprising that this mutation 
did not afford protection against cisplatin treatment in the current investigation. 
Repeating the experiments using other ovarian cancer cell lines such as SKOV-3, 
will be required to determine if p53
R175H‟s inability to protect against cell death is 
specific to just HCT-116 cells. 
 
5.4 Concluding Remarks 
 
The major focus of this segment of the study is to determine if p53 can 
augment cell survival in the presence of a cytotoxic drug, by reducing caspase-9 
activity. From the results obtained, the hypothesis was proven true for WT and the 
various mutant p53 studied, with the exception of the R175H mutant. It hence 
appears that in an in vivo environment, the structure of p53 is important in the 
inhibition of caspase-9, since both mutants with slight (p53
R337H
) or drastic structural 
changes (p53
R175H
) showed compromised or no significant reduction in caspase-9 
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activity, and weakened cytoprotection against cisplatin. Intriguingly, the 
cytoprotection was also evident in cells overexpressing WTp53, suggesting the 
inhibition of caspase-9 as an inherent role of the WT protein and provides a 
mechanistic explanation to the phenomenon of WTp53 overexpression in various 
cancers. 
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Chapter 6 
 
Conclusion 
 
6.1 General Discussion 
 
6.1.1 The Two Facets of p53 
 
 The results from this study demonstrated the inhibitory actions of p53 (both 
WT and mutant) on caspase-9 using several methods. This inhibition occurred 
through the direct interaction of p53 and the p35 active caspase-9 fragment, resulting 
in the suppression of caspase-9‟s activities both in vivo and in vitro. In addition, the 
enhanced resistance of cells to the cytotoxic effects of cisplatin in a p53-null 
background can be attributed to the reduction of caspase-9 activity. Taken together, 
the data obtained strongly suggest that p53 possesses an inherent anti-apoptotic 
function in the cell. This is in stark contrast to its very well-known tumour 
suppression functions. This unexpected activity of p53 uncovered by this study may 
well be the first report of such nature, even though the phenomenon that p53 can 
enhance survival of tumour cells has already been recorded for some time.  
Although the anti-apoptotic function of p53 discovered in this study is novel, 
the idea that proteins can execute seemingly contradicting roles is not. In fact, there 
are already several examples of proteins with both facilitating and antagonising 
functions, switching to and fro between the two depending on circumstances. One 
known example of such is the c-myc protein. 
 
6.1.1.1 c-myc, a Protein with “Contradicting” Roles 
 
Like p53, c-myc is a transcriptional factor [287]. However, in contrast to p53, 
c-myc promotes cell cycle progression through the activation of transcriptional 
factors such as E2F1 [288] and E2F2 [289]. Also, it transcriptionally represses cell 
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cycle checkpoint genes like GADD45 and GADD153 [290]. In addition, it inhibits 
the function of cyclin-dependent kinase (CDK) inhibitors [291], either through direct 
repression of gene transcription or indirectly through degradation or sequestration. 
For cell differentiation to occur, downregulation of c-myc is required [292,293]. 
Apart from its functions to promote cell growth, c-myc can also initiate angiogenesis 
through the release of interleukin 1β [294]. 
The contrasting face of c-myc lies in its ability to induce apoptosis through 
direct interaction and activation of Bax [295] and indirectly inhibiting the functions 
of Bcl-2 [296] and Bcl-xL [297]. B-cells that were deficient in c-myc proteins were 
reported to be resistant to diverse apoptotic stimuli [298]. Interestingly, pathways 
involving c-myc and p53 crosstalk. In a study by Zindy [299], deregulated c-myc 
upregulated ARF, which in turn activate p53. The activated p53 then transactivate 
target genes involved in apoptosis and growth arrest. 
 
6.1.1.2 Transforming Growth Factor-beta (TGFβ), Another Example 
 
Another example of such proteins is TGFβ. TGFβ is a group of ligands 
consisting of TGFβ1, TGFβ2 and TGFβ3, acting through two receptors, namely 
TGFβ type 1 (TGFB1) and type 2 (TGFB2) receptors [300,301]. Upon activation, the 
phosphorylated receptors recruit and phosphorylate receptor‑regulated Smads 
(R‑Smads) [302] proteins. Activated R‑Smads then form heteromeric complexes 
with SMAD4 and translocate into the nucleus [300]. The Smad complexes then 
regulate the expression of genes through the association with other transcription 
factors such as the forkhead, homeobox, zinc‑finger, AP1, and basic helix–loop–
helix (bHLH) families [303,304]. In addition, it can also repress transcription by 
associating with co‑repressors such as retinoblastoma‑like 1 (RBL1) [305]. Hence, 
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depending on which proteins partner with the Smad complexes in the nucleus 
downstream of TGFβ binding, the target genes can be either activated or repressed.  
TGFβ can either promote or inhibit cell proliferation, although the two 
scenarios are dependent on cell type. TGFβ can inhibit cell cycle progression in the 
G1 phase through the induction of cyclin‑dependent kinase inhibitors (CDKIs), 
InK4B and p21 [306,307]. TGFβ also represses the expression of c-myc [308]. In 
blood related cancers such as acute myeloid leukaemia, the human ecotropic viral 
integration site 1 (evI1) protein is transcriptionally activated by several recurrent 
chromosomal aberrations [309]. evI1 interacts with SMAD3 (an R-Smad protein) 
and antagonizes the growth inhibitory effects of TGFβ [310]. In another example, 
Tax, a transcriptional protein produced by the human T-cell leukaemia virus type I 
(and implicated in various clinical manifestations in adult T cell leukaemia), disrupts 
the interaction of Smad complexes with the transcriptional co‑activator p300 and 
contributes to resistance to growth inhibition by TGFβ [311,312]. In addition to the 
anti-proliferation activities, TGFβ can initiate the transcription of proapoptotic target 
genes such as BIM [313]. Bim promotes apoptosis by binding to Bcl-2 [314], thereby 
relieving its inhibitory effect on Bax, allowing Bax to induce the release of 
cytochrome-c [315].  
In some other cell types, TGFβ appears to promote proliferation. For 
example, in certain mesenchymal cells (including smooth muscle cells), TGFβ 
enhances cell division through the induction of platelet‑derived growth factor 
(PDGF) [316]. Overexpression of TGFβ was shown to be associated with a poor 
prognosis in patients with glioma [317]. Consistent with its pro-proliferation 
function, TGFβ can influence apoptosis through the transactivation of anti-apoptotic 
genes. Differentially expressed in Chondrocytes 1 (DeC1), a target of TGFβ [318], is 
Chee Lai Yuen  
139 
 
a bHLH transcription factor which could in turn activate the expression of Survivn 
[319], thereby inhibiting apoptosis. DeC1 has been found to be frequently 
overexpressed in certain cancers, including breast carcinomas [320].  
 
6.1.2 A Balance is Needed 
 
Due to the dual roles of p53 uncovered in this study, it appears now that cells 
are constantly balancing its pro-apoptotic and anti-apoptotic functions. As reviewed 
in Chapter 1, p53 is a node for the regulation of multiple cellular functions. Cells are 
not just sensitive to the activation state of p53, but also to the levels of the protein in 
the cellular environment. In cancer, the protein level of p53 is often affected, thereby 
contributing to the tumorigenesis and aggressiveness of the tumour cells. 
Protein levels of a gene can be determined by the gene copy in a cell. Cells 
are extremely sensitive to the haploid/diploid state of the p53 gene. Mice that are 
p53
+
/
-
 showed enhanced tumour formation [321]. This suggests that one copy of the 
p53 gene is inadequate in eliciting sufficient levels of apoptosis, which could be due 
to the reduced transactivation of pro-apoptotic genes and the ability to initiate 
apoptosis directly at the mitochondria. Further evidence of the importance of p53 
protein level regulation for normal cell growth, cells with haploid MDM2/4 (the 
negative regulators of p53 level) showed increased cell death, and the phenomenon 
can be corrected by a concurrent deletion of one copy of the p53 gene [322]. 
In cancer, this skewed p53 protein level is highly detrimental. A tumour cell 
with p53 mutation is analogous to a p53
+
/
-
 environment. These tumour cells are 
usually heterozygous for p53 mutation, containing one allele carrying the mutation, 
while the other allele codes for the WT protein. As the mutant p53 can no longer 
carry out the functions of its WT counterpart, the decreased level of functional WT 
proteins probably account for the enhanced growth of these cells [323,324]. Not to 
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mention, there are additional mechanisms which have been suggested and reported 
that contribute to the aggressive nature of the tumour cells. This include the 
hypothesis that mutant p53 usually becomes dominant-negative by influencing the 
functions of the remaining WTp53 proteins through the formation of hetero-
oligomers with WTp53. This interaction was found to change the conformation of 
the WTp53 proteins, hence inhibiting the normal functions of the WT protein [191]. 
A more detailed review has been presented in Section 1.4.3.2. In addition, there are 
many articles reporting the overexpression of mutant p53 in tumours. Hence, while 
the lowered levels of the WT protein could account for the reduced apoptosis, the 
elevated concentration of the mutant p53 could confer resistance to chemotherapeutic 
drugs. In this study, the uncovered function of p53‟s inhibition of caspase-9 can be a 
contributing factor to the enhanced resistance and aggressiveness of these tumour 
cells. 
Not all tumour cells carry a p53 mutation. In fact, some tumours were found 
to overexpress the WTp53 protein instead. Accumulation of WTp53 in the cytoplasm 
has been reported in colorectal cancer [325], brain [326], breast and neuroblastoma 
[175,176]. Noon [327] reported that increased p53 expression contributed to reduced 
overall survival and more rapid disease progression in renal cell carcinoma. As 
cytoplasmically localised p53 was found to be resistant to ubiquitin-dependent 
degradation by MDM2 [328], the persistent presence of the WT protein in the 
cytoplasm could increase the threshold of the cells to apoptosis through the inhibition 
of caspase-9. The significance of this is that even in the face of its ability to induce 
the activation of Bax and the release of cytochrome-c, the ability of p53 to inhibit 
caspase-9 would still stem the progression of apoptosis, hence enhancing the 
capacity of these cells to survive.  
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6.1.3 Implications for Future Research and Therapies 
 
With the discovery of p53‟s anti-apoptotic function as reported herein, the 
idea of activating endogenous p53 to the WT conformation would now need to 
include this new dimension of p53. As shown in several reports, the simple activation 
of p53 did not always yield the desired results of inducing more cell death. While 
studies by both Liu [329] and Song [330] demonstrated that viral-vector induced 
expression of WTp53 resulted in sensitisation of the transduced cells to the effects of 
irradiation and cisplatin, others have demonstrated that the induction of WTp53 did 
not increase apoptosis [331]. On the contrary, some work reported increased 
resistance after the introduction of WTp53 [332,333]. As such, more research has to 
be done to investigate if these transduced WTp53 are functionally similar to 
endogenous WTp53 in normal cells.  
Apart from introducing WTp53 that are functionally active, the localisation of 
the protein should also be looked into. Reports mentioned earlier have demonstrated 
the higher chemoresistance in tumours with cytoplasmic accumulation of p53. 
Therefore, based on the results of this investigation, a cytoplasmic localisation would 
result in the inhibition of cytoplasmic caspase-9 activity, resulting in lowered 
sensitivity to apoptosis. At the current level of understanding, the introduction of a 
functional WTp53 that could enter the nucleus to perform its transactivation role to 
induce apoptosis would produce the best results, although the implications of 
activating other cellular processes such as cell cycle arrest and senescence should not 
be ignored. Another way, as discussed in Section 1.5.3, is to target MDM2/X, the 
negative regulators of p53. As both proteins are in the nucleus, the relief of the 
inhibition by MDM2/X would directly release WTp53 into the nuclear milieu, 
allowing it to perform its pro-apoptotic, transactivating functions. Also, the balance 
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between the levels of WT and mutant p53 proteins (in the case of tumours 
harbouring p53 mutation) must be analyzed before effective gene therapy can be 
administered.  
The ideas suggested above are by no means exhaustive. Due to the dynamic 
nature of the cellular environment and the complex pathways involving p53, it will 
take more years of intensive research to completely understand the full functions of 
this intriguing protein. Only then, can p53 be manipulated successfully through the 
use of gene therapy, to obtain the desired outcome in treating cancer with 
dysfunctional p53. However, the challenge now will be to take into consideration this 
newly discovered role of p53 when designing therapies targeting cancers with p53 
mutations and/or overexpression. 
 
6.2 Critical Analysis and Future Works 
 
 Although the work performed for this study have provided evidence to prove 
the inhibitory effect of p53 on caspase-9 activity through direct interaction, more 
research work are needed to gain deeper insights into this novel p53 function. 
 
6.2.1 Improvements to Experiments Done in this Study 
 
 Firstly, a few improvements can be done to experiments already performed in 
this study. A criticism of current work can be seen in Chapter 3, whereby the 
immunodepletion and knockdown of p53 in A2780 cells did not manage to show 
very significant differences in the enhancement of caspases and PARP protein 
cleavage (Figures 3.5 and 3.7). This was partly due to the difficulty in achieving 
substantial reduction in the p53 levels in both experiments. To better determine the 
impact of p53 reduction on caspase cleavage and activation on this cell line, further 
optimisation can be done in terms of increasing the knockdown duration, increasing 
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the concentration of the siRNA specific for p53 used,  and increasing antibody 
concentration used for immunodepleting p53 from the lysates. The experiments can 
also be repeated in other ovarian cell lines with WTp53, such as OVCAR-4 or Sk-
OV-3. 
 Similarly, the difference in the caspase-9 activities in PEO4 cells was not 
very obvious between the control and the one with p53 knockdown (Figure 3.8D). As 
seen from the Western blot for p53 levels (Figure 3.8E), there was no marked 
reduction of p53 protein level.  Again, optimisation of the knockdown duration and 
dosage of siRNA should be performed for future works.  
 Another criticism is the observation that for cisplatin-sensitive PEO1 cell 
line, the measured caspase-9 activity of the control population upon cisplatin 
challenged (as compared to PBS) did not increase considerably (Figure 3.8B). It is 
possible that the number of times of passage for this cell line used during the 
experiment was too high. Also, the dosage of cisplatin used (25µM) may be 
overwhelming for this cisplatin-sensitive cell line, possibly resulting in massive 
necrosis which could not be detected in this experimental set up. In order to 
substantiate or verify that the cisplatin resistance in PEO4 cell lines were due to p53, 
PEO1 cells must first show sensitivity to cisplatin dosage in the control population, 
while displaying a lesser extent of increased caspase-9 activities, as compared to 
PEO4, upon p53 knockdown. Hence, a repeat of this set of experiments with lower 
cisplatin dosage is desirable. 
 The use of the PEO cell lines provided a p53 mutant background to study the 
effects of reducing endogenous mutant p53 on caspase-9 activities. However, only 
one such cell line was used on this study. To better show the inhibition of caspase-9 
by mutant p53 in vivo, the use of other cell lines bearing mutations of p53 at other 
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sites could be incorporated. This may include ovarian cell lines such as 2274 and 
TOV-112D, both bearing hot-spot mutations R273H and R175H respectively [152]. 
In addition, cell lines of other backgrounds e.g. breast cancer cell line HCC1395 
[334] and colon cancer cell line SW480 [335] can be used to reinforce the hypothesis 
of this study. 
 The general trend displayed by the results presented in Chapter 3 was that 
increasing p53 levels corresponded to reduced caspase-9 cleavage/activities. 
However, overexpression of WTp53 appears to not support this correlation. In Figure 
3.9, the low levels of expression of WTp53 resulted in the inhibition of caspase-9, 
while much higher WTp53 levels resulted in the restoration of caspase-9 activity 
levels to that of the control. As discussed, this does not mean that WTp53 does not 
inhibit caspase-9. Rather, the pro-apoptotic effects observed with high p53 level, 
possibly due to the transactivation activities of WTp53, could contribute to the 
phenomenon observed. This actually provides an excellent case study to investigate 
the balance between the transactivation effects of p53 and the inhibition of caspase-9 
activities by endogenous WTp53. To start, the concentration of plasmids used for 
overexpression can be further fine-tuned, to determine the tipping point in reversal of 
caspase-9 inhibition. In the meantime, the expression of pro-apoptotic target genes of 
p53 such as Bax or Bak can be probed using immunoblotting to determine their 
involvement in this phenomenon. Indeed, the use of an inducible cell line and careful 
measurement of p53 levels using a quantitative assay could give valuable 
information about the precise p53 level that controls this tipping point. 
 In Chapter 4, the specificity of the recombinant p53 refolded and used for 
many of the experiments in this study were shown by testing the inhibitory effect on 
other recombinant caspases such as caspase-3 and caspase-6 (Figure 4.2). The main 
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point of criticism here is that both caspases used are considered „effector‟ caspases 
i.e. caspases which are downstream in the apoptotic pathways and their structural 
difference to „initiator‟ caspases could have resulted in the lack of inhibition by the 
recombinant p53 [336]. As such, the inclusion of other „initiator‟ caspases such as 
caspase-8 would further validate the specificity of the recombinant p53 used.  
Also in Chapter 4, IP and cross-linking were used to demonstrate the 
interaction between the recombinant p53 and endogenous caspase-9 (Figure 4.6). 
However, the control beads showed „contamination‟ of p53 and caspase-9. As 
discussed, the presence of both proteins could be due to the lack of stringency in the 
washing steps involved in the procedure before the cross-linking step. Further 
optimisation is hence needed to show a clear cut difference between the control (with 
the use of HST-tag), and the one with p53, so as to demonstrate unequivocally that 
the interaction is purely between p53 and caspase-9.  
 Lastly, in Chapter 5, the increase in cell survival through inhibition of 
caspase-9 was demonstrated using only one cell line and one type of drug. To show 
that this is a generic phenomenon, repeats of this experiment using other p53-null 
cell lines of other backgrounds (such as bone cell line, Saos-2 and lung carcinoma 
H1299) and other chemotherapeutic drugs (e.g. Actinomycin-D and etoposide) can 
be included. Also, other techniques such as cologenic assays and fluorescence 
activated cell sorting (FACS) analysis for Annexin V and propidium iodide can be 
used as additional methods to determine the changes in cell survival in response to 
cytotoxins in the presence of p53.  
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6.2.2 Domain Study to Investigate the Point of Interaction between p53 and Caspase-
9 
 
 Since p53 has been shown to interact with caspase-9, it will be interesting to 
study the detailed mechanism of interaction. Firstly, domain studies can be 
performed to narrow down the point of interaction between these two proteins, and to 
investigate further the conditions in which such interaction/inhibition occurs. As it 
has been shown and discussed that the interaction between the two is transient and 
cannot be properly investigated using traditional IP experiments, other methods need 
to be employed. As demonstrated in Chapter 4, far Western coupled with cross-
linking has been used successfully. By modifying this technique, the interaction 
site(s) can be potentially mapped out. This can be firstly done by producing 
recombinant p53 of various domains (e.g. the TAD only, TAD and DBD, DBD only 
etc), refolding it, and applying it as bait proteins to renatured active caspase-9 
proteins on the nitrocellulose membranes, in order to elucidate which domain(s) is 
essential for the interaction. Next, site-directed mutagenesis of the identified 
domain(s) can be performed to pinpoint the site or amino acid(s) critical for this 
interaction. Similarly, this can be repeated for the p35 domain of caspase-9 to 
determine the crucial sites involved in the interaction.  
 A further extension of this study would be to overexpress the genes of both 
proteins bearing mutation to the critical sites to investigate if apoptosis can still be 
abrogated upon chemotherapeutic drug challenge. This would hence link the 
interaction of these proteins to enhanced cell survival, and possibly, the increased 
drug resistance in tumour cells. 
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6.2.3 Impact of Post-translational Modifications of p53 and Caspase-9 
 
 As this may be the first report to show the inhibitory effects of p53 on 
caspase-9, this study has concentrated on demonstrating the phenomenon of the 
inhibition as well as proving the interaction between these two proteins. However, it 
must be highlighted that both proteins may be subjected to post-translational 
modifications, which can influence the inhibitory effect observed so far. 
 As reviewed in Section 1.3, p53 can undergo extensive post-translational 
modifications to regulate its activities. In particular, phosphorylation of p53 at 
residue 46 has been shown to be involved in initiating apoptosis [285,337]. The 
enhanced resistance of p53-null cells overexpressing the D42Y mutant has been 
hypothesised in Chapter 5 to be partly due to the abrogation of this phosphorylation. 
Hence, it will be interesting to find out the phosphorylation status of p53 in the cell 
lines overexpressing the various mutant and WTp53.  
 Also reviewed in the same section, acetylation of p53 at various residues 
could bring about enhanced p53 activities either through the disruption of negative 
regulation of p53 by MDM2/MDM4 [128,129], or by increasing the cytoplasmic 
presence of p53, and thereby apoptosis [133]. Major sites of acetylation include 
lysine residues at position 164 and 320 [129,130,132], both of which are in close 
proximity to R175H and R337H mutations respectively. It will be interesting to see if 
acetylation was involved. It is possible that through the constitutive acetylation of 
p53, which brings forth an extended half-life of the p53 proteins, increased 
cytoplasmic localisation of p53 hence ensues, thereby resulting in the inhibition of 
caspase-9 and apoptosis. 
 Similar to p53, caspase-9 can also be regulated through post-translational 
modification. So far, phosphorylation of the protein has been identified to inhibit its 
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activity. Phosphorylation of serine 196 by Akt [338] and threonine 125 by ERK 
[339] and CDK1/cyclinB1 [340] inhibit caspase-9 activities and apoptosis. It will 
hence be worthwhile to study if the inhibition of p53 on caspase-9 involves the 
phosphorylation of caspase-9, both directly on the protein or indirectly through the 
influence of the other proteins responsible for the modifications. 
 To study the post-translational states of p53 and caspase-9, antibodies 
specific to these modifications are available commercially for detection through 
Western blot. By comparing the levels of such modification in the different 
experimental conditions, a better understanding of the relationship between this and 
the reduced level of apoptosis observed can be achieved. 
 
6.2.4 Involvement of p53 in the Apoptosome 
 
Caspase-9 forms part of the apoptosome with other proteins like Apaf-1 and 
cytochrome-c [341], leading to the activation of caspase-9 and caspase-3 [84]. Many 
studies focusing on the formation of the apoptosome as well as caspase activation 
have provided evidence to show that the activation of caspase-9 is dependent on 
dimerization [342] and association with the apoptosome complex [84][343].  
In this study, p53 was shown to directly associate with caspase-9 and 
bringing about the inhibition of its activities. In an in vitro environment whereby 
caspase-9 is in an extremely high concentration, recombinant cleaved caspase-9 can 
easily dimerize to be active and hence the inhibition of its activities by recombinant 
p53 can be easily observed (Figures 4.1 and 4.3). In a cell-free and in vivo 
environment, due to the presence of endogenous Apaf-1, dATP and the added 
cytochrome-c, activation of caspase-9 can be achieved and similarly, inhibition of its 
cleavage can be detected (Figures 3.2 to 3.12). Combining these two findings, it 
seems to suggest that the mechanism of p53‟s inhibitory action on caspase-9 is to 
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firstly interact with the p35 active fragment, followed by the inhibition of its ability 
to cleave more procaspase-9 proteins, hence preventing the amplification of this 
apoptotic pathway. However, the results presented are inadequate in proving this 
hypothesis and it also could not show the relationship between the inhibition 
mechanism and the apoptosome. It will be interesting to see if p53 mount its „attack‟ 
through sequestering active caspase-9 from the apoptosome, or by directly binding to 
the active caspase-9 fragment while it is part of the apoptosome complex, hence 
preventing the cleavage and activation of downstream proteins such as caspase-3 and 
PARP. 
As the molecular weight of the apoptotsome complex (not including p53) is 
massive (>1MDa), the study of this structure had to be done using gel filtration 
techniques. Shiosaki [344] published his findings of the oligomerisation and 
activation of caspase-9 with the CARD domain of Apaf-1. Gel filtration, combined 
with Western blot, was used to elucidate the interaction of caspase-9 with Apaf-1 
CARD, as interacting complexes will elute in different volumes due to the change in 
molecular weight. Similarly, this technique can be employed to study the 
involvement of p53 and the apoptosome.  
 
6.2.5 Involvement of p53 Family of Proteins 
 
The „gain-of-function‟ of mutant p53 has already been long suspected by the 
scientific community although concrete evidences of its mechanism have not yet 
surfaced. Gaiddon [345] has demonstrated that mutant p53 could interact with p63 
and p73 (both proteins related in sequence and structure to p53) and inhibit the 
transcriptional activities of these two proteins, resulting in reduced apoptosis and 
tumorigenesis.  
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In this study, the question whether the inhibitory role of p53 on caspase-9 is 
the sole mechanism in inhibiting apoptosis could not be addressed. It would be hence 
helpful to test if the involvement of the other two p53 family members affects 
apoptotic signalling as well. Mutations of the p53 gene, which can affect the 
interaction between the members of this family of proteins, can be generated to study 
if interaction of p53 and p63/p73 proteins will influence the p53-mediated cell death 
resistance already observed in this study. 
In addition, elevated expression of p73 has been demonstrated in cells 
exposed to cisplatin [346]. Also, p73 was shown to increase the level of apoptosis 
[347] while the downregulation of its expression resulted in enhanced 
chemoresistance [348]. It would hence be beneficial to investigate if p73 protein 
levels are affected in cells overexpressing the various p53 and subjected to cisplatin 
challenge, and whether this contributed to the increased resistance to cisplatin. 
 
6.2.6 Primary Cell Lines and Clinical Applications 
 
The work done here involved the use of only immortalised cell lines. As this 
is a first effort to demonstrate the relationship between p53 and caspase-9, no 
research has been attempted on primary cell lines and animal models as yet. To prove 
that this inhibitory effect of p53 on caspase-9 is not just found in immortalised 
cancer cell lines, a repeat of the experiments using primary cell lines can be done. 
Also, the use of animal models with knock-in p53 mutation can also provide protein 
samples to verify the findings of this study. Similarly, clinical samples bearing p53 
mutations are also valuable resources to give an added avenue to validate the results 
obtained. 
In addition to the above, the results from this investigation have shown that 
the inhibition of caspase-9 could be possibly linked to cisplatin resistance (Figure 
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3.8D). Moreover, cells overexpressing the D42Y mutation (found in ovarian cancer 
tumours) displayed huge resistance to cisplatin and enhanced cell survival. As 
hypothesised earlier in this report, the abrupt change of amino acids properties with 
charged side chains to those bearing a benzene ring in the mutant could adversely 
affect the functions of normal p53, hence resulting in the augmented resistance to 
chemotherapeutic drugs observed. With this, it will be interesting to investigate the 
relationship between adverse change in side chain properties in tumours bearing p53 
mutation and drug resistance. This can be achieved by sequencing the p53 genes of 
patient samples before and after cisplatin resistance, and looking out for changes in 
the p53 gene status (in particular for any side chain changes with vastly different 
properties), to correlate the two events. From here, the presence of such mutation 
could potentially be used as a biomarker for chemotherapeutic drug resistance, hence 
potentially allowing better design of treatment therapies for such cases.  
 
6.3 Final Conclusion 
 
The results obtained so far have provided evidence for a novel 
transcriptional-independent role of p53 in caspase inhibition. The direct interaction 
of p53 and active caspase-9 is the first report of such nature. In addition, the 
inhibition is evident not just in the mutant form, but also WTp53, which proves that 
this inhibitory role is an inherent p53 function. Its significance is such that firstly, the 
inhibition of an apical caspase bears consequential effects in preventing and/or 
substantially delaying a full-scale activation of the apoptotic pathway and thereby 
cell death. Secondly, this mechanism is downstream of p53‟s pro-apoptotic functions 
in terms of transactivation of Bax and Bak and the direct activation of Bax to result 
in cytochrome-c release. The ability of p53 to halt the progression of the very 
pathway it activates enable p53 to better regulate the whole progression of apoptosis, 
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allowing it to arrest cell death at the final moments before they are doomed to self 
destruct.  
Although the inhibitory role of p53 has been proven in this study, more work 
has to be done, especially in the validation of the mechanism in primary cell lines, 
animal models, and clinical samples. Only then can it be safely concluded that such 
mechanism is an inherent function of p53. Upon the verification of this new role of 
p53, drug therapy design aimed at simply transducing cells to express WTp53 could 
no longer be sufficient. Localisation of the protein and the balance between WT and 
mutant p53 protein levels must also be optimised.  
In conclusion, based on the knowledge of p53 functions so far, the delicate 
balance between the amounts of pro-apoptotic genes transactivated by p53, activated 
pro-apoptotic proteins, and the physical presence of p53 in the cytoplasm for caspase 
inhibition, is critical to the cell‟s survival. Any perturbation to this fragile balance, in 
particular in a diseased background, would affect cell fate and ultimately the overall 
survival of an individual.  
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